SlideShare ist ein Scribd-Unternehmen logo
1 von 136
LESSON 12
Paying for Care and Health Information
LEARNING OUTCOMES
_____________________________________________________
_________________________
In this lesson, you will do the following:
Describe how coding, reimbursement, and billing are impacted
by health information systems.
READINGS
The following reading assignments are for Lessons 9 through
12:
Gartee Text:
Chapter 4, pp. 74 - 95
Chapter 5, pp. 98 - 126
Chapter 6, pp. 127 - 151
Chapter 9, pp. 208 - 236
Chapter 10, pp. 237 - 259
ACTIVITIES / ASSESSMENTS
The following activities/assessments are for Lessons 9 through
12:
1. Read the assigned pages from the Gartee text.
2. Review the Lecture Notes, Unit 3 PowerPoint, and Voice
Pod.
3. Participate in the weekly discussion question.
4. Complete the written assignment.
WRITTEN ASSIGNMENTS
Hospital Medicare Payment System - DRGs:
Research how large hospitals are paid by a Medicare fee for
service reimbursements (DRG’s).
Include a brief history and relate how health information
supports the request for a payment.
PLEASE NOTE: All graded assignments for the lessons in this
unit should be grouped together
and submitted as ONE document using the Assignment
Submission form accessed from your
course homepage or http://www.sjcme.edu/gps/assignments.
All activities/assignments for this unit should be as follows:
1. Should include a cover sheet for each assignment stating the
following:
2. Each individual assignment number and copy of the
assignment directions should be
included in the submission as the starting header of each lesson.
3. Carefully check grammar and spelling.
4. Use APA format for any research or sources that are being
used or quoted.
5. Email the instructor if you have questions regarding the
assignments.
http://www.sjcme.edu/gps/assignments
g
Research www.AJOG.org
O B S T E T R I C S
Preterm premature rupture of membranes >32 weeks’
estation: impact of revised practice guidelines
Arij Faksh, DO; Joseph R. Wax, MD; F. Lee Lucas, PhD;
Angelina Cartin; Michael G. Pinette, MD
OBJECTIVE: The purpose of this study was to determine the
perinatal
impact of the 2007 American College of Obstetricians and
Gynecolo-
gists Practice Bulletin on preterm premature membrane rupture.
STUDY DESIGN: Perinatal outcomes were compared in women
who
had experienced preterm membrane rupture in the 3 years before
the
2007 Practice Bulletin to similar women who experienced
preterm pre-
mature rupture of membranes in the 3 years after the issue and
imple-
mentation of the guideline.
RESULTS: After adjustment for gestational age at membrane
rupture
and steroids, composite severe morbidity (death, respiratory
distress
Obstet Gynecol 2011;205:340.e1-5.
p
remained uncertain, p
doi: 10.1016/j.ajog.2011.05.036
340.e1 American Journal of Obstetrics & Gynecology
OCTOBER 2011
syndrome, assisted ventilation for �6 hours, sepsis, pneumonia,
grade
3 or 4 intraventricular hemorrhage, or necrotizing enterocolitis)
was
similar by group. Infants in the “after” group experienced less
pneumo-
nia and sepsis, similar respiratory morbidity, but more labor
inductions
and postpartum hemorrhage.
CONCLUSION: The new guideline significantly decreases
severe neo-
natal infections but is associated with more frequent labor
induction and
postpartum hemorrhage.
Key words: neonatal morbidity, prematurity, preterm premature
rupture of membranes
Cite this article as: Faksh A, Wax JR, Lucas FL, et al. Preterm
premature rupture of membranes �32 weeks’ gestation: impact
of revised practice guidelines. Am J
m
c
p
o
t
Preterm premature rupture of mem-branes (PPROM) affects 1-
2% of
pregnancies but is associated with up to
30-40% of preterm births.1 In the ab-
sence of labor or complications that war-
rant delivery, expectant care is often
practiced until a gestational age is
reached beyond which further observa-
tion does not significantly reduce pre-
maturity complications but potentially
exposes the fetus to infection and in-
flammation with associated long-term
From the Division of Maternal-Fetal
Medicine, Department of Obstetrics and
Gynecology (Drs Faksh, Wax, and Pinette
and Ms Cartin), and the Maine Center for
Outcome Research and Evaluation (Dr Lucas),
Maine Medical Center, Portland, ME.
Received Feb. 9, 2011; revised April 5, 2011;
accepted May 18, 2011.
J.R.W. reports having served periodically as a
consultant to the Gerson Lehrman Group over
the past 3 years. The other 4 authors report no
conflicts of interest.
Presented orally at the District I Meeting,
American College of Obstetricians and
Gynecologists, Bar Harbor, ME, Oct. 8-10,
2010.
Reprints not available from the authors.
0002-9378/$36.00
© 2011 Mosby, Inc. All rights reserved.
negative consequences. Contemporary
PPROM management incorporates glu-
cocorticoids, broad-spectrum antibiot-
ics, and fetal lung maturity assessment.
Perinatal outcomes that are associated
with this care suggest that expectancy
may be abandoned at earlier gestational
ages than previously considered.2-5
In April 2007, the American College of
Obstetricians and Gynecologists (ACOG)
published a revised Practice Bulletin that
supported more active PPROM manage-
ment at earlier gestational ages.6 However,
2 of 3 recommendations regarding deliv-
ery timing were based on limited and in-
consistent scientific evidence (level B) and
included delivery at 32-33 weeks’ gestation
with documented fetal lung maturity or
when PPROM occurred at �34 weeks’
gestation. An additional recommendation
to consider a single course of corticoste-
roids at 32-33 weeks’ gestation, particu-
larly if pulmonary immaturity was docu-
mented, was based primarily on consensus
and expert opinion (level C). Moreover,
many supporting studies were conducted
among predominantly African American
women,3-5 whose offspring demonstrate
accelerated lung maturation compared
with white women.7,8 Thus, the antici-
ated benefits of the new practice guideline
articularly in a pri-
arily white population. We therefore
onducted a retrospective study that com-
ared short-term maternal and neonatal
utcomes before vs after the implementa-
ion of the 2007 Practice Bulletin.
ME T H O D S
This retrospective, institutional review
board– exempt study included all women
with a single living nonanomalous fetus
who had experienced PPROM at 32 0/7 to
35 6/7 weeks’ gestation from January 1,
2004, to April 1, 2010, and who received
care in a single tertiary teaching hospital. A
best obstetric estimate of gestational age
was determined with the use of menstrual
data and first- or second-trimester ultra-
sonography. Rupture of membranes was
diagnosed by sterile speculum examina-
tion that confirmed the pooling of amni-
otic fluid in the vagina, positive nitrazine
paper test, and positive ferning test. Those
women with PPROM in the 3 years before
guideline implementation on April 1,
2007, were compared with those with
PPROM in the subsequent 3 years with re-
gard to maternal and newborn character-
istics and outcomes. The primary outcome
was composite severe neonatal morbidity
(any one of the following occurrences:
death, respiratory distress syndrome [RDS],
assisted ventilation for �6 hours, sepsis,
t
�
v
o
r
a
c
a
s
i
l
e
t
n
a
o
a
p
l
f
e
011.
www.AJOG.org Obstetrics Research
pneumonia, grade 3 or 4 intraventricular
hemorrhage [IVH], or necrotizing entero-
colitis). Secondary outcomes included
neonatal intensive care unit (NICU) ad-
mission, NICU length of stay, respiratory
morbidity (RDS or assisted ventilation for
�6 hours), and infectious morbidity (cul-
ture-proven sepsis or pneumonia).
Women in the “before” group re-
ceived inpatient care that consisted of a
single course of glucocorticoid therapy
at 32 0/7 to 33 6/7 weeks’ gestation, a
2-day course of intravenous ampicillin
followed by 5 days of oral amoxicillin,
and a single 1-g oral dose of azithromy-
cin. Tocolytics were used at physician
discretion for up to 48 hours to permit
steroid administration. Fetal surveil-
lance included daily biophysical profiles
and nonstress tests every 4-8 hours. De-
livery ensued after spontaneous labor,
documentation of fetal lung maturity by
the presence of phosphatidylglycerol in
amniotic fluid that was obtained from
the vaginal pool or by amniocentesis at
32-36 weeks’ gestation, when 35-36
weeks’ gestation was achieved or sooner
for nonreassuring fetal status or clinical
chorioamnionitis.
Women in the “after” group received
identical care, which varied only with re-
gard to delivery timing. Again, delivery
followed spontaneous labor, nonreas-
suring fetal status, or clinical chorioam-
nionitis. Alternatively, women in the af-
TABLE 1
Maternal characteristics
Demographic Before
Age, ya 28.4 �
...............................................................................................
....................
Body mass index, kg/m2a 31.2 �
...............................................................................................
....................
White, n (%) 103 (96
...............................................................................................
....................
Parity, n
...............................................................................................
...........
0 69
...............................................................................................
...........
1 19
...............................................................................................
...........
�2 19
...............................................................................................
....................
Tobacco use, n (%) 34 (31
...............................................................................................
....................
Previous loop electric excision
procedure/cone biopsy, n (%)
8 (7.
...............................................................................................
....................
a Data are given as mean � SD.
Faksh. Revised PPROM guideline. Am J Obstet Gynecol 2
ter group were also delivered at 32 0/7 to t
33 6/7 weeks’ gestation if amniotic fluid
was obtained from the vaginal pool or by
amniocentesis and demonstrated that
phosphatidylglycerol was present. If the
fluid could not be collected or lung ma-
turity was not demonstrated, delivery
was initiated at 34 0/7 weeks’ gestation.
Finally, delivery was expedited on ad-
mission for PPROM after 34 0/7 weeks’
gestation. As of September 2008, a
change in NICU admission policy oc-
curred, whereby all infants who were
born after PPROM �36 0/7 weeks’ ges-
tation were admitted to the NICU or
intermediate care nursery where they re-
mained until hospital discharge. Pre-
viously, 35-week infants were triaged in
the delivery room based on respiratory
status. Infants who were born at �35 0/7
in both time periods routinely were ad-
mitted to the NICU; those infants who
were born at �36 weeks’ gestation in
both time periods were triaged in the de-
livery room based on respiratory status.
Maternal characteristics, management,
interventions, and outcomes were com-
pared by study group. Morbidity included
chorioamnionitis (diagnosed by �2 of
he following occurrences: maternal fever
38.0°C, uterine tenderness, malodorous
aginal discharge, maternal leukocytosis,
r fetal tachycardia), postpartum hemor-
hage (estimated blood loss �500 mL after
vaginal delivery and �1000 mL after a
esarean delivery), postpartum endome-
107) After (n � 64) P value
.8 26.4 � 6.1 .04
...............................................................................................
...................
.9 31.5 � 7.9 .81
...............................................................................................
...................
62 (96.9) .83
...............................................................................................
...................
.66
...............................................................................................
...................
39
............................................................................... ................
...................
15
...............................................................................................
...................
10
...............................................................................................
...................
22 (34.4) .73
...............................................................................................
...................
5 (7.8) .94
.............................................................................................. .
...................
ritis (maternal temperature of �38.0°C
OCTOBER 2011 Americ
fter the first 24 postpartum hours with as-
ociated uterine tenderness), and wound
nfection (periincisional erythema, puru-
ent drainage, or induration in the postop-
rative period that required antibiotic
herapy).
Data were abstracted from the mater-
al prenatal record, and the maternal
nd newborn inpatient records. Dichot-
mous and continuous variables were
nalyzed with the chi-square and un-
aired t-test, respectively. Logistic and
inear regression analyses were adjusted
or covariates. Significance was consid-
red for a probability value of � .05.
RE S U L T S
One hundred seventy-one eligible subjects
were included: 107 women before and 64
women after guideline implementation.
Maternal demographics were similar by
study group (Table 1). Women who were
cared for under the new guideline were less
likely to be treated expectantly, despite
having experienced PPROM at an earlier
average gestational age. They also more of-
ten received steroids to accelerate fetal lung
maturity. After adjustment for differences
in gestational age at PPROM, this group
more often had labor induced and deliv-
ered on average 1 week earlier than women
with PPROM before the new guideline
(Table 2). Despite the increased induction
rate, primary and total cesarean delivery
rates were similar by group. Maternal mor-
bidity, including clinical and histologic
chorioamnionitis, occurred with similar
frequency by study group, except for the
later cohort that experienced more post-
partum hemorrhages. There were no
blood transfusions, however, in any sub-
jects (Table 3).
Newborn infant outcomes were ad-
justed for differences in gestational age at
PPROM and steroid administration.
There was no significant difference in the
frequency of composite morbidity by
time period (Table 4). No infant had a
severe IVH or necrotizing enterocolitis.
There were 2 cases of suspected intra-
uterine growth restriction (estimated fe-
tal weight or abdominal circumference
�10% for gestational age) in the before
group and 1 case in the after group. The
(n �
5
.........
6
.........
.3)
.........
.........
.........
.........
.........
.8)
.........
5)
.........
only death occurred from disseminated
an Journal of Obstetrics & Gynecology 340.e2
.
o
s
c
p
p
b
w
2
a
i
s
A
m
g
l
t
p
t
a
p
o
i
e
b
w
3
t
s
p
v
f
p
i
011.
Research Obstetrics www.AJOG.org
herpes infection in a newborn infant of a
mother with no history or physical find-
ings of infection. Neonates who were
born after guideline implementation
were more likely to be admitted to the
NICU and experience longer NICU
stays. These offspring had significantly
fewer diagnoses of severe infections, yet
no significantly increased rate of respira-
tory complications (Table 4). Infants in
the before group weighed more than
those in the after group (2387 � 373 g vs
2233 � 365 g; P � .009). There was no
difference in the frequency of 5-minute
Apgar scores of �7 (1.9% vs 4.7%; P �
3).Umbilical arterial cord blood pH was
btained in all cases; no infant demon-
trated a pH �7.00.
CO M M E N T
Our study demonstrates that the imple-
mentation of and adherence to recent
PPROM management guidelines signif-
icantly reduces the composite outcome
of neonatal sepsis and pneumonia with-
out increasing newborn infant compos-
ite morbidity among women who expe-
rience PPROM at �32 weeks’ gestation.
However, this benefit is associated with
significantly more frequent maternal la-
bor induction, postpartum hemorrhage,
increased NICU use, and a statistically
nonsignificant increase in respiratory
morbidity. Importantly, the increased
induction rate did not raise the primary
or overall cesarean delivery rates, and no
maternal transfusions were required.
The increased NICU use that was ob-
served under the new guideline likely re-
flects, at least in part, the described
change in neonatal admission policy.
These results provide important data
regarding the 2007 ACOG PPROM prac-
tice bulletin recommendations, particu-
larly regarding delivery timing. Several
supporting studies that were referenced
by the bulletin included mostly urban
African American women, who com-
prised 55-79.6% of the subjects.3-5 After
ontrolling for population differences,
reterm infants born to black women ex-
erience significantly less hyaline mem-
rane disease than those born to white
omen on a week-by-week basis from
6-37 weeks.7 Therefore, the generaliz- B
340.e3 American Journal of Obstetrics & Gynecolo
bility of the earlier findings and result-
ng practice recommendations to dis-
imilar populations remained uncertain.
lthough the difference in respiratory
orbidity rates between our study
roups was not statistically significant, a
arger study population could result in
his difference becoming significant. A
ost hoc sample size calculation showed
hat 257 patients in each group would
chieve statistical significance with 80%
ower at the .05 level.
A recent evaluation of ACOG Practice
TABLE 2
Management of preterm premature
Characteristics Be
Gestational age at PPROM, wka 3
...............................................................................................
....................
Gestational age at delivery, wka 3
...............................................................................................
....................
Expectant care, n (%) 7
...............................................................................................
....................
Latency, da,c
...............................................................................................
....................
Steroids, n (%) 6
...............................................................................................
....................
Antibiotics, n (%) 10
...............................................................................................
....................
Tocolytic, n (%) 2
...............................................................................................
....................
Amniotic fluid tested for maturity, n (%) 7
...............................................................................................
....................
Amniotic fluid test mature, n (%) 3
...............................................................................................
....................
Labor induction, n (%) 2
...............................................................................................
...........
Indications
...............................................................................................
..
34 wk
...............................................................................................
..
Lung maturity 2
...............................................................................................
..
Clinical chorioamnionitis
...............................................................................................
..
Nonreassuring fetal status
...............................................................................................
....................
Cesarean delivery, n (%)
...............................................................................................
...........
Primary 2
...............................................................................................
...........
Total 3
...............................................................................................
...........
Indications
...............................................................................................
..
Nonreassuring fetal status 1
...............................................................................................
..
Malpresentation
...............................................................................................
..
Cephalopelvic disproportion
...............................................................................................
..
Chorioamnionitis
...............................................................................................
..
Repeat
...............................................................................................
..
Elective
...............................................................................................
..
Abruption
...............................................................................................
....................
PPROM, preterm premature rupture of membranes.
a Data are given as mean � SD; b Adjusted for gestational a
expectantly; d Adjusted for gestational age at PPROM and st
Faksh. Revised PPROM guideline. Am J Obstet Gynecol 2
ulletins observed that only 23% of rec-
gy OCTOBER 2011
mmendations regarding obstetrics top-
cs were based on good and consistent
vidence (level A).9 The 2007 PPROM
ulletin offered 11 recommendations, of
hich 5 (45%) were level A. Notably, 2 of
recommendations regarding delivery
iming were based on limited and incon-
istent scientific data. Moreover, although
ractice guidelines should reduce practice
ariation and improve health outcomes,
ew studies evaluate these intended and
otentially unintended consequences of
mplementation.10 Therefore, it is impor-
pture of membranes
e (n � 107) After (n � 64) P value
� 1.0 33.2 � 0.9 .0001
...............................................................................................
...................
� 0.9 33.6 � 0.8 .0001b
...............................................................................................
...................
1.0) 34 (53.1) .02
...............................................................................................
...................
� 4.0 4.5 � 3.2 .57
...............................................................................................
...................
4.5) 54 (84.4) .004
...............................................................................................
...................
00) 63 (98.4) NS
...............................................................................................
...................
3.4) 11 (17.2) .34
...............................................................................................
...................
5.4) 22 (34.3) .001d
...............................................................................................
...................
4.3) 6 (27.7) .4
...............................................................................................
...................
7.1) 35 (54.7) � .0001d
...............................................................................................
...................
...............................................................................................
...................
26
...............................................................................................
...................
4
...............................................................................................
...................
3
...............................................................................................
...................
2
...............................................................................................
...................
...............................................................................................
...................
3.4) 15 (23.4) .53
...............................................................................................
...................
2.7) 18 (28.1)
...............................................................................................
...................
...............................................................................................
...................
8
...............................................................................................
...................
4
...............................................................................................
...................
2
...............................................................................................
...................
1
...............................................................................................
...................
1
......................................................................................... ......
...................
2
...............................................................................................
...................
0
...............................................................................................
...................
t PPROM; c Includes only those patients who were managed
s.
ru
for
3.9
.........
4.4
.........
6 (7
.........
4.9
.........
9 (6
.........
7 (1
.........
5 (2
.........
0 (6
.........
1 (4
.........
9 (2
.........
.........
0
.........
6
.........
2
.........
1
.........
.........
5 (2
.........
5 (3
.........
.........
2
.........
9
.........
3
.........
3
.........
6
.........
1
.........
1
.........
ge a
eroid
tant to examine a guideline’s impact on
t
i
l
c
o
a
r
t
t
a
a
e
c
d
q
a
T
g
f
I
n
p
b
c
t
i
a
t
T
p
w
011.
www.AJOG.org Obstetrics Research
populations that are different from those
that generated the recommendations, par-
ticularly when the recommendations were
based on inconsistent supporting evi-
dence. Our data confirm the anticipated
benefits of less frequent neonatal infec-
tious morbidity. However, the results raise
questions about the neonatal respiratory
consequences of current delivery recom-
mendations after PPROM in a 97% white
population. The increased frequencies of
labor induction and postpartum hemor-
rhage also deserve further attention.
Seven randomized trials that have cov-
ered a total of 690 subjects have examined
expectant vs planned early delivery in
TABLE 3
Maternal morbidity
Outcome Be
Chorioamnionitis, n (%)
...............................................................................................
...........
Clinical 10
...............................................................................................
...........
Histologic 47
...............................................................................................
....................
Postpartum hemorrhage, n (%) 5
............................................................................................. ..
....................
Transfusion, n 0
...............................................................................................
....................
Endometritis or wound infection, n (%) 4
...............................................................................................
....................
Faksh. Revised PPROM guideline. Am J Obstet Gynecol 2
TABLE 4
Neonatal outcomesa
Outcome
Primary, n (%)
......................................................................................... ......
...........
Death
...............................................................................................
...........
Respiratory distress syndrome
............................................................................................. ..
...........
Assisted ventilation
...............................................................................................
...........
Sepsis
...............................................................................................
...........
Pneumonia
...............................................................................................
...........
Grade 3/4 intraventricular hemorrhage
...............................................................................................
...........
Necrotizing enterocolitis
...............................................................................................
...........
Composite
...............................................................................................
....................
Secondary
...............................................................................................
...........
Neonatal intensive care unit
............................................................................................. ..
..
Admission, n (%)
...............................................................................................
..
Stay, db
...............................................................................................
...........
Respiratory morbidity, n (%)
...............................................................................................
...........
Infectious morbidity, n (%)
...............................................................................................
....................
a Adjusted for gestational age at preterm premature rupture o
Faksh. Revised PPROM guideline. Am J Obstet Gynecol 2011.
pregnancies that were complicated by
PPROM.3-5,11-14 These studies are difficult
o compare with each other and with our
nvestigation because of many methodo-
ogic differences, such as the time period
overed by the study, the gestational ages
f included subjects, the administration of
ntibiotics and steroids, tocolytic use, the
ole of amniotic fluid fetal lung maturity
esting in pregnancy management, the
iming of planned delivery after PPROM,
nd the outcome measures. A recent meta-
nalysis of these trials found that planned
arly delivery was associated with in-
reased rates of labor induction, cesarean
elivery, and endometritis but less fre-
e (n � 107) After (n � 64) P value
...............................................................................................
...................
3) 5 (7.8) .73
............................................................................... ................
...................
.9) 20 (31.3) .10
...............................................................................................
...................
7) 12 (18.8) .003
...............................................................................................
...................
0 —
...............................................................................................
...................
7) 1 (1.6%) .39
...............................................................................................
...................
ore (n � 107) After (n � 64) P value
...............................................................................................
...................
(0.9) 0 .81
...............................................................................................
...................
(11.2) 14 (21.9) .23
...............................................................................................
...................
(17.8) 21 (32.8) .06
...............................................................................................
...................
(4.7) 1 (1.6) .08
...............................................................................................
...................
(7.5) 1 (1.6) .14
...............................................................................................
...................
0 —
...............................................................................................
...................
0 —
...............................................................................................
...................
(23.4) 21 (32.8) .42
...............................................................................................
...................
...............................................................................................
...................
...............................................................................................
...................
(72.9) 62 (96.9) .03
...............................................................................................
...................
2 � 3.3 5.0 � 3.2 .05
...............................................................................................
...................
(18.9) 21 (32.8) .09
...............................................................................................
...................
(11.2) 2 (3.2) .04
...............................................................................................
...................
mbranes and steroids; b Data are given as mean � SD.
OCTOBER 2011 Americ
uently with suspected neonatal infection
nd newborn infant antibiotic treatment.
here were no differences by group re-
arding perinatal, neonatal, or intrauterine
etal deaths or morbidities of IVH or RDS.
nterestingly, frequencies of chorioamnio-
itis, positive neonatal blood cultures, and
neumonia were not significantly different
y management approach. The authors
oncluded that insufficient evidence exists
o guide clinical decision-making regard-
ng immediate delivery vs expectant man-
gement of PPROM, citing inadequate sta-
istical power.1
A prospective cohort study compared
neonatal outcomes after expectant vs elec-
tive delivery of PPROM between 24 0/7 to
33 6/7 weeks’ gestation. Similar to our
management, antepartum care included
antibiotics and steroids. As in the current
report, the frequency of RDS was statisti-
cally similar in both groups, although sep-
sis was less frequent with elective delivery.
Contrasting our findings, a significant re-
duction in the rate of grade 3 or 4 IVH led
to a decrease in severe composite morbid-
ity among electively delivered infants,
probably related to the earlier gestational
ages of included PPROM subjects. This
group also had a higher cesarean delivery
rate, which reflected the increased inci-
dence of nonvertex presenting fetuses,
again likely a consequence of early gesta-
tional ages at membrane rupture.2
A retrospective investigation of pa-
tients who experience PPROM at �24
weeks’ gestation and who delivered at
�37 weeks’ gestation from 1998-2000
examined maternal and neonatal com-
plications to determine an ideal gesta-
tional age for delivery. Steroids and
broad-spectrum antibiotics were admin-
istered routinely. If phosphatidylglycerol
was present in vaginal pool fluid at �32
weeks’ gestation, delivery was expedited.
When compared with pregnancies with
PPROM delivery at 36 0/7 to 36 6/7 weeks’
gestation, major and minor composite
neonatal morbidity were increased among
those infants who were delivered at �33
and �34 weeks’ gestation, respectively.
he authors questioned the benefit of ex-
ectant management of PPROM at �34
eeks’ gestation.15
The limited short-term neonatal bene-
for
.........
(9.
.........
(43
.........
(4.
.........
.........
(3.
.........
Bef
.........
1
.........
12
.........
19
.........
5
.........
8
.........
0
.........
0
.........
25
.........
.........
.........
78
.........
3.
.........
20
.........
12
.........
f me
fits of expectant management of PPROM
an Journal of Obstetrics & Gynecology 340.e4
1
s
a
o
a
n
a
Research Obstetrics www.AJOG.org
that were noted in the current and earlier
studies likely reflect several factors. Con-
temporary maternal and neonatal care that
features antepartum steroids, broad-spec-
trum antibiotics, selective tocolytic use,
and improved NICU care are probable
contributors to the observed outcomes.
Additionally, the relatively short latency
period that is anticipated with expectant
care of PPROM at �34 weeks’ gestation
may be insufficient to favorably impact
short-term neonatal outcomes. One re-
port noted latencies at �48 hours in only
0.4% of such cases.16 Another article de-
cribed a mean latency of 2.4 � 3.1 days
mong these women.15 The similarly short
mean latency intervals that we observed,
coupled with later mean gestational ages of
PPROM that were studied, support this
explanation.
Chorioamnionitis and the accompa-
nying inflammatory response have been
implicated in adverse long-term neuro-
logic sequelae among exposed offspring.17
An important rationale for the active man-
agement of PPROM is to minimize the
risks that are associated with such expo-
sures. However, contrasting most previous
studies, we found no differences in the
rates of clinical or histologic chorioamnio-
nitis between expectantly and actively
managed PPROM.3,4,5,11 We suspect that
ur findings reflect the shorter latencies
nd less frequent inflammation that are
oted with PPROM at later gestational
ges, such as those included in our study.18
This observation is strengthened by the
availability of placental pathologic findings
for all subjects in both time periods of our
study.
Our report offers several strengths be-
yond those already mentioned. Data were
drawn from a single institution with 1 ma-
ternal fetal medicine group and 1 neona-
tology group providing consistent patient
care. One institutional guideline for ante-
partum care was in effect for each time pe-
riod. No obstetrical practice changes other
than delivery timing resulted from guide-
line implementation. Neonatal practice
changed only with regard to the described
admission policy. Therefore, we believe
that the observed results, with the possible
exception of NICU use, likely stem from
the revised delivery policy. We recognize
several limitations, including the retro-
340.e5 American Journal of Obstetrics & Gynecolo
spective study design and population
differences among subjects in the 2 time
periods that were examined. However, re-
gression analyses adjusted for differences
in confounders between the 2 groups. Be-
cause the patients were drawn from a ter-
tiary referral center, the data may not re-
flect population-based rates of the various
outcome measures. Although the homo-
geneity of our population was a strength in
addressing our research question, it may
limit generalizability of our results to dis-
similar patients.
In summary, the implementation of the
2007 ACOG PPROM Practice Bulletin
guidelines in our population significantly
reduced severe neonatal infectious mor-
bidity without significantly exacerbating
composite morbidity. However, these
benefits must be balanced against in-
creased induction and hemorrhage rates,
coupled with concerns for increased neo-
natal respiratory morbidity. We also ob-
served increased intensive care use, even
after adjusting for earlier gestational age at
PPROM and increased steroid use, which
may reflect changes in neonatal admission
policy. Additional research should also
evaluate the cost-effectiveness of imple-
mentation of the guideline’s recommen-
dations and the subsequent impact on
long-term childhood pulmonary, neuro-
logic, and developmental sequelae. A ran-
domized trial of expectant vs active man-
agement of PPROM at �32 weeks’
gestation would shed important light on
these uncertainties. f
REFERENCES
1. Buchanan SL, Crowther CA, Levett KM,
Middleton P, Morris J. Planned early birth ver-
sus expectant management for women with
preterm prelabour rupture of membranes prior
to 37 weeks’ gestation for improving pregnancy
outcome. Cochrane Database Syst Rev 2010;
3:CD004735.
2. Pasquier JC, Picaud JC, Rabilloud M, et al.
Neonatal outcomes after elective delivery man-
agement of preterm premature rupture of the
membranes before 34 weeks’ gestation
(DOMINOS study). Eur J Obstet Gynecol Re-
prod Biol 2009;143:18-23.
3. Mercer BM, Crocker LB, Boe NM, Sibai BM.
Induction versus expectant management in pre-
mature rupture of the membranes with mature
amniotic fluid at 32 to 36 weeks: a randomized
trial. Am J Obstet Gynecol 1993;169:775-82.
4. Naef RW, Allbert JR, Ross EL, Weber BM,
Martin RW, Morrison JC. Premature rupture of
gy OCTOBER 2011
membranes at 34 to 37 weeks’ gestation:
aggressive versus conservative management.
Am J Obstet Gynecol 1998;178:126-30.
5. Cox SM, Leveno KJ. Intentional delivery ver-
sus expectant management with preterm rup-
tured membranes at 30-34 weeks’ gestation.
Obstet Gynecol 1995;86:875-9.
6. American College of Obstetricians and Gyne-
cologists. Premature rupture of membranes:
ACOG practice bulletin no. 80. Obstet Gynecol
2007;109:1007-19.
7. Hulsey TC, Alexander GR, Robillard PY, Anni-
bale DJ, Keenan A. Hyaline membrane disease:
the role of ethnicity and maternal risk characteris-
tics. Am J Obstet Gynecol 1993;168:572-6.
8. Richardson DK, Torday JS. Racial differences
in predictive value of the lecithin/sphingomyelin
ratio. Am J Obstet Gynecol 1994;170:1273-8.
9. Chauhan SP, Berghella V, Sanderson M,
Magann EF, Morrison JC. American College of
Obstetricians and Gynecologists practice bulle-
tins: an overview. Am J Obstet Gynecol 2006;
194:1564-75.
10. Shackelton RJ, Marceau CD, Link CL,
McKinlay JB. The intended and unintended
consequences of clinical guidelines. J Eval Clin
Pract 2009;15:1035-42.
11. Spinnato JA, Shaver DC, Bray EM, Lipshitz J.
Preterm premature rupture of the membranes
with fetal pulmonary maturity present: a prospec-
tive study. Obstet Gynecol 1987;69:196-201.
12. Garite TJ, Freeman RK, Linzey EM, Braley
PA, Dorchester WL. Prospective randomized
study of corticosteroids in the management of
premature rupture of the membranes and the
premature gestation. Am J Obstet Gynecol
1981;141:508-15.
13. Iams JD, Talbert ML, Barrows H, Sacks L.
Management of preterm prematurely ruptured
membranes: a prospective randomized com-
parison of observation versus use of steroids
and timed delivery. Am J Obstet Gynecol
1985;151:32-8.
14. Nelson LH, Meis PJ, Hatjis C, Ernest JM,
Dillard R, Schey HM. Premature rupture of
membranes: a prospective, randomized evalu-
ation of steroids, latent phase, and expectant
management. Obstet Gynecol 1985;66:55-8.
15. Lieman JM, Brumfield CG, Carlo W, Ram-
sey PS. Preterm premature rupture of mem-
branes: is there an optimal gestational age for
delivery? Obstet Gynecol 2005;105:12-7.
16. Neerhof MG, Cravello C, Haney EI, Silver RK.
Timing of labor induction after premature rupture
of membranes between 32 and 36 weeks’ ges-
tation. Obstet Gynecol 1999:180:349-52.
17. Shatrov JG, Birch SC, Lam LT, Quinlivin JA,
McIntyre S, Mendz GL. Chorioamnionitis and
cerebral palsy: a meta-analysis. Obstet Gynecol
2010;116:387-92.
18. Ramsey PS, Lieman JM, Brumfield CG,
Carlo W. Chorioamnionitis increases neonatal
morbidity in pregnancies complicated by pre-
term premature rupture of membranes. Am J
Obstet Gynecol 2005;192:1162-6.
Preterm premature rupture of membranes ≥32 weeks` gestation:
impact of revised practice g
...MethodsResultsCommentReferences
918 VOL. 122, NO. 4, OCTOBER 2013 OBSTETRICS &
GYNECOLOGY
Background
The definition of PROM is rupture of membranes before
the onset of labor. Membrane rupture before labor and
before 37 weeks of gestation is referred to as preterm
PROM. Management is influenced by gestational age
and the presence of complicating factors, such as clini-
cal infection, abruptio placentae, labor, or nonreasurring
fetal status. An accurate assessment of gestational age
and knowledge of the maternal, fetal, and neonatal risks
are essential to appropriate evaluation, counseling, and
care of patients with PROM.
Etiology of Premature Rupture of
Membranes
Membrane rupture may occur for a variety of reasons.
Although membrane rupture at term can result from
a normal physiologic weakening of the membranes
combined with shearing forces created by uterine
contractions, preterm PROM can result from a wide
array of pathologic mechanisms that act individually
or in concert (4, 5). Intraamniotic infection has been
shown to be commonly associated with preterm PROM,
especially at earlier gestational ages (6). A history of
preterm PROM is a major risk factor for preterm PROM
or preterm labor in a subsequent pregnancy (7, 8).
Additional risk factors associated with preterm PROM
are similar to those associated with spontaneous preterm
birth and include short cervical length, second-trimester
and third-trimester bleeding, low body mass index, low
socioeconomic status, cigarette smoking, and illicit drug
use (9–12). Although each of these risk factors is associ-
ated with preterm PROM, it often occurs in the absence
of recognized risk factors or an obvious cause.
Term Premature Rupture of Membranes
At term, PROM complicates approximately 8% of preg-
nancies and generally is followed by the prompt onset of
spontaneous labor and delivery. In a large randomized
trial, one half of women with PROM who were managed
expectantly gave birth within 5 hours and 95% gave birth
within 28 hours of membrane rupture (13). The most
Premature Rupture of Membranes
Preterm delivery occurs in approximately 12% of all births in
the United States and is a major factor that contributes
to perinatal morbidity and mortality (1, 2). Preterm premature
rupture of membranes (PROM) complicates approxi-
mately 3% of all pregnancies in the United States (3). The
optimal approach to clinical assessment and treatment of
women with term and preterm PROM remains controversial.
Management hinges on knowledge of gestational age and
evaluation of the relative risks of delivery versus the risks of
expectant management (eg, infection, abruptio placentae,
and umbilical cord accident). The purpose of this document is to
review the current understanding of this condition
and to provide management guidelines that have been validated
by appropriately conducted outcome-based research
when available. Additional guidelines on the basis of consensus
and expert opinion also are presented.
Committee on Practice Bulletins—Obstetrics. This Practice
Bulletin was developed by the Committee on Practice
Bulletins—Obstetrics with the assis-
tance of Robert Ehsanipoor, MD. The information is designed to
aid practitioners in making decisions about appropriate obstetric
and gynecologic care.
These guidelines should not be construed as dictating an
exclusive course of treatment or procedure. Variations in
practice may be warranted based on the
needs of the individual patient, resources, and limitations
unique to the institution or type of practice.
NUMBER 139, OCTOBER 2013 (Replaces Practice Bulletin
Number 80, April 2007 and
Committee Opinion Number 475, February 2011)
P RACTICE BULLET IN
CLINICAL MANAGEMENT GUIDELINES FOR
OBSTETRICIAN–GYNECOLOGISTS
The American College of
Obstetricians and Gynecologists
WOMEN’S HEALTH CARE PHYSICIANS
VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin
Premature Rupture of Membranes 919
significant maternal consequence of term PROM is
intrauterine infection, the risk of which increases with
the duration of membrane rupture.
Preterm Premature Rupture of
Membranes
Regardless of obstetric management or clinical presen-
tation, birth within 1 week of membrane rupture occurs
in at least one half of patients with preterm PROM (5).
Latency after membrane rupture is inversely correlated
with the gestational age at membrane rupture (14).
Cessation of amniotic fluid leakage with restoration of
normal amniotic fluid volume may occur in the setting
of spontaneous preterm PROM and is associated with
favorable outcomes (15).
Among women with preterm PROM, clinically
evident intraamniotic infection occurs in approxi-
mately 15–25% (16), and postpartum infection occurs
in approximately 15–20%; the incidence of infection is
higher at earlier gestational ages (6, 17). Abruptio pla-
centae complicates 2–5% of pregnancies with preterm
PROM (18, 19).
The most significant risks to the fetus after preterm
PROM are complications of prematurity. Respiratory
distress has been reported to be the most common com-
plication of preterm birth (20). Sepsis, intraventricular
hemorrhage, and necrotizing enterocolitis also are asso-
ciated with prematurity, but these are less common near
to term. Preterm PROM with intrauterine inflammation
has been associated with an increased risk of neurode-
velopmental impairment (21, 22), and early gestational
age at membrane rupture also has been associated with
an increased risk of neonatal white matter damage (23).
However, there are no data that suggest that immediate
delivery after presentation with PROM will avert these
risks. Infection and umbilical cord accident contribute
to the 1–2% risk of antenatal fetal demise after preterm
PROM (24).
Previable Premature Rupture of
Membranes
Rupture of the membranes before viability occurs in
less than 1% of pregnancies. The probability of neonatal
death and morbidity associated with PROM decrease with
longer latency and advancing gestational age (25). In a
review of preterm PROM between 14 weeks and 24 weeks
of gestation, perinatal deaths were more or less equally
divided between stillbirths and neonatal deaths. Survival
rates were much improved with expectant management
following membrane rupture after 22 weeks of gestation
compared with membrane rupture before 22 weeks of
gestation (57.7% versus 14.4%, respectively) (26).
Most studies of second-trimester and previable
PROM are retrospective and include only expectantly
managed cases. Thus, they likely overestimate survival
rates because of selection bias. Survival data may vary
by institution.
Significant maternal complications that occur after
previable PROM include intraamniotic infection, endo-
metritis, abruptio placentae, and retained placenta (26).
Although it occurs infrequently, life-threatening mater-
nal infection may complicate expectant management of
previable PROM. Maternal sepsis is reported in approxi-
mately 1% of cases (26), and isolated maternal deaths
due to infection have been reported in this setting.
Latency periods appear to be prolonged with
second-trimester preterm PROM compared with later
gestational ages. However, 40–50% of patients with
previable PROM will give birth within the first week and
approximately 70–80% will give birth 2–5 weeks after
membrane rupture (26–28).
The rate of pulmonary hypoplasia after PROM
before 24 weeks of gestation varies widely among
reports, but is likely in the range of 10–20%. Pulmonary
hypoplasia is associated with a high risk of mortality
(26), but is rarely lethal with membrane rupture sub-
sequent to 23–24 weeks of gestation (29), presumably
because alveolar growth adequate to support postnatal
development already has occurred. Early gestational age
at membrane rupture, and low residual amniotic fluid
volume are the primary determinants of the incidence of
pulmonary hypoplasia (30, 31).
Prolonged oligohydramnios also can result in fetal
deformations, including Potter-like facies (eg, low-set
ears and epicanthal folds) and limb contractures or other
positioning abnormalities. The reported frequency of
skeletal deformations varies widely (1.5–38%) but many
of these resolve with postnatal growth and physical
therapy (26, 32).
Clinical Considerations and
Recommendations
How is premature rupture of membranes
diagnosed?
Most cases of PROM can be diagnosed on the basis of
the patient’s history and physical examination. Exam-
ination should be performed in a manner that minimizes
the risk of introducing infection. Because digital cervical
examinations increase the risk of infection and add little
information to that available with speculum examina-
tion, digital examinations generally should be avoided
unless the patient appears to be in active labor or delivery
920 Practice Bulletin Premature Rupture of Membranes
OBSTETRICS & GYNECOLOGY
seems imminent (33, 34). Sterile speculum examination
provides an opportunity to inspect for cervicitis and
umbilical cord prolapse or fetal prolapse, assess cervi-
cal dilatation and effacement, and obtain cultures as
appropriate.
The diagnosis of membrane rupture typically is
confirmed by the visualization of amniotic fluid pass-
ing from the cervical canal and pooling in the vagina; a
basic pH test of vaginal fluid; or arborization (ferning)
of dried vaginal fluid, which is identified under micro-
scopic evaluation. The normal pH of vaginal secretions
is generally 4.5–6.0, whereas amniotic fluid usually has
a pH of 7.1–7.3. False-positive test results may occur
in the presence of blood or semen, alkaline antiseptics,
or bacterial vaginosis. Alternatively, false-negative test
results may occur with prolonged membrane rupture and
minimal residual fluid.
In equivocal cases, additional tests may aid in the
diagnosis. Ultrasonographic examination of amniotic
fluid volume may be a useful adjunct, but is not diag-
nostic. Fetal fibronectin is a sensitive but nonspecific
test for ruptured membranes; a negative test result is
strongly suggestive of intact membranes, but a positive
test result is not diagnostic of PROM (35). Several com-
mercially available tests for amniotic proteins are cur-
rently on the market, with high reported sensitivity for
PROM (36, 37). However, false-positive test result rates
of 19–30% have been reported in patients with clinically
intact membranes and symptoms of labor (38, 39). These
test kits should be considered ancillary to standard meth-
ods of diagnosis. If the diagnosis remains unclear after
a full evaluation, membrane rupture can be diagnosed
unequivocally with ultrasonographically-guided transab-
dominal instillation of indigo carmine dye, followed by
the passage of blue-dyed fluid into the vagina, which is
documented by a stained tampon or pad. It is important
to note that the maternal urine also will turn blue and
should not be confused with amniotic fluid.
What does the initial management involve
once PROM has been confirmed?
In all patients with PROM, gestational age, fetal presen-
tation, and fetal well-being should be determined. The
examination should evaluate for evidence of intrauterine
infection, abruptio placentae, and fetal compromise.
If results are not already available and if an indication
for treatment is not already present, culture for group B
streptococci (GBS) should be obtained when expectant
management is being considered.
In patients with preterm PROM, an initial period of
electronic fetal heart rate monitoring and uterine activity
monitoring offers the opportunity to identify abnormal
fetal heart rate tracings and to evaluate for contrac-
tions (40). Management after confirmation of the diag-
nosis of PROM is dependent primarily on gestational
age and is discussed in more detail in the follow-
ing paragraphs. Nonreassuring fetal status and clinical
chorioamnionitis are indications for delivery. Vaginal
bleeding should raise concern for abruptio placentae and
also should prompt consideration of delivery, with the
decision based on fetal status, the amount of bleeding,
and gestational age.
What is the optimal method of initial
management for a patient with PROM
at term?
Gestational age and fetal position should be confirmed
and fetal heart rate monitoring should be used to assess
fetal status. Group B streptococcal prophylaxis should
be given based on prior culture results or intrapartum
risk factors if cultures have not been previously per-
formed (41).
A meta-analysis of 12 randomized controlled trials
(6,814 women) found that induction of labor reduced the
time to delivery and the rates of chorioamnionitis, endo-
metritis, and admission to the neonatal intensive care
unit without increasing the rates of cesarean delivery or
operative vaginal delivery (42). The largest of these trials
also found that women viewed induction of labor more
positively than expectant management (13). Induction of
labor with prostaglandins has been shown to be equally
effective for labor induction compared with oxytocin but
is associated with higher rates of chorioamnionitis (13).
Infection is also a concern with mechanical methods of
cervical ripening, such as the Foley balloon, but there are
insufficient data on which to base a recommendation for
mechanical methods of cervical ripening in the setting of
PROM. A meta-analysis of two trials suggests that use
of prophylactic antibiotics may reduce infectious mor-
bidity, but prompt induction of labor was not standard
care in either study. Thus, there is insufficient evidence
to justify the routine use of prophylactic antibiotics with
PROM at term in the absence of an indication for GBS
prophylaxis (43–45).
These meta-analysis data indicate that patients ben-
efitted from induction of labor compared with expectant
management and suggest that for women with PROM
at 37 0/7 weeks of gestation or more, if spontaneous
labor does not occur near the time of presentation in
those who do not have contraindication to labor, labor
should be induced, generally with oxytocin infusion.
However, a course of expectant management may
be acceptable for a patient who declines induction of
labor as long as the clinical and fetal conditions are
VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin
Premature Rupture of Membranes 921
reassuring and she is adequately counseled regarding
the risks of prolonged PROM. During induction of labor
with oxytocin, a sufficient period of adequate contrac-
tions (at least 12–18 hours) should be allowed for the
latent phase of labor to progress before diagnosing failed
induction and moving to cesarean delivery (46–48).
When is delivery recommended for the
preterm fetus in the presence of premature
rupture of membranes?
Nonreassuring fetal status, clinical chorioamnionitis,
and significant abruptio placentae are clear indications
for delivery. Otherwise, gestational age is a primary fac-
tor when considering delivery versus expectant manage-
ment (Box 1).
However, the optimal gestational age for delivery
is unclear and controversial. A meta-analysis of seven
randomized controlled trials, including 690 women,
concluded there was insufficient evidence to guide clini-
cal practice regarding the risks and benefits of expectant
management versus delivery in the setting of preterm
PROM (49). The trials were insufficiently powered, had
methodological weaknesses, and were variable in the
gestational ages included.
More recently, two randomized controlled trials
evaluated delivery versus expectant management between
34 weeks and 37 weeks of gestation and included a total
of 736 women (50, 51). Combining data from the two
studies, induction of labor did not produce a statisti-
cally significant reduction in the rate of neonatal sepsis
(2.7% at 34 weeks versus 4.1% at 37 weeks of gestation,
relative risk [RR], 0.66; 95% confidence interval [CI],
0.3–1.5). However, induction of labor did significantly
reduce the risk of chorioamnionitis (1.6% at 34 weeks
versus 5.3% at 37 weeks of gestation, RR, 0.31; 95%
CI, 0.1–0.8), although there were no other significant
differences between the two groups. These studies did
not have sufficient power to show a statistically signifi-
cant reduction in the rate of neonatal sepsis because the
overall rate of sepsis was lower than anticipated. These
findings are consistent with other smaller, similarly
designed trials (52, 53) and those conducted in women
at term (13, 42).
Despite these data, the optimal gestational age for
delivery remains controversial. Recently there has been
a focus on the short-term (54) and long-term (55)
risks associated with late preterm birth. However, the
relevance of this to the management of women with
ruptured membranes is unclear because neonates born
from pregnancies complicated by preterm PROM have a
higher rate of adverse outcomes compared with controls
matched for gestational age (56). Furthermore, chorio-
amnionitis, prolonged membrane rupture, and oligohy-
dramnios are risk factors for adverse neonatal outcomes
with preterm PROM (56, 57).
At 34 0/7 weeks or greater of gestation, delivery is
recommended for all women with ruptured membranes.
If expectant management is continued beyond 34 0/7
weeks of gestation, the balance between benefit and risk
should be carefully considered and discussed with the
patient, and expectant management should not extend
beyond 37 0/7 weeks of gestation. Patients with PROM
before 34 0/7 weeks of gestation should be managed
Box 1. Chronologic Management of
Premature Rupture of Membranes
Early Term and Term (37 0/7 weeks of gestation or
more)
Late Preterm (34 0/7–36 6/7 weeks of gestation)
Preterm (24 0/7–33 6/7 weeks of gestation)* †
Less than 24 weeks of gestation‡
†
‡
922 Practice Bulletin Premature Rupture of Membranes
OBSTETRICS & GYNECOLOGY
Should antenatal corticosteroids be
administered to patients with preterm
PROM?
The use of antenatal corticosteroid administration after
preterm PROM has been evaluated in a number of
clinical trials and has been shown to reduce neonatal
mortality, respiratory distress syndrome, intraventricu-
lar hemorrhage, and necrotizing enterocolitis (64, 65).
Current data suggest that antenatal corticosteroids are not
associated with increased risks of maternal or neonatal
infection regardless of gestational age. A single course
of corticosteroids is recommended for pregnant women
between 24 0/7 weeks and 34 0/7 weeks of gestation
who are at risk of preterm delivery (66). A Cochrane
meta-analysis reinforces the beneficial effect of this
therapy regardless of membrane status and concludes
that a single course of antenatal corticosteroids should be
considered routine for all preterm deliveries (64). There
are no data that support the use of corticosteroids before
viability, and administration of corticosteroids in this
setting is not currently recommended.
Weekly administration of corticosteroids has been
associated with a reduction in birth weight and head cir-
cumference and is not recommended (67–69). Whether
to administer a rescue course of corticosteroids with
PROM is controversial, and there is insufficient evi-
dence to make a recommendation for or against.
Should magnesium sulfate for fetal neuro-
protection be administered to patients with
preterm PROM?
Randomized controlled trials have demonstrated that
maternal administration of magnesium sulfate used for
fetal neuroprotection when birth is anticipated before 32
0/7 weeks of gestation reduces the risk of cerebral palsy
in surviving infants (RR, 0.71; 95% CI, 0.55–0.91) (70).
In the largest of these trials, 85% of the women enrolled
had preterm PROM between 24 weeks and 32 weeks
of gestation (71). The optimal treatment regimen for
fetal neuroprotection remains unclear, and different
regimens were used in different trials. Hospitals that
elect to use magnesium sulfate for fetal neuroprotec-
tion should develop uniform and specific guidelines
for their departments regarding inclusion criteria, treat-
ment regimens, concurrent tocolysis, and monitoring
in accordance with one of the larger trials (71–73).
Regardless of the treatment regimen used, women with
preterm PROM before 32 0/7 weeks of gestation who
are thought to be at risk of imminent delivery should
be considered candidates for fetal neuroprotective treat-
ment with magnesium sulfate.
expectantly if no maternal or fetal contraindications
exist (53).
What general approaches are used in cases
of preterm PROM managed expectantly?
Expectant management of preterm PROM generally
consists of hospital admission with periodic assess-
ment for infection, abruptio placentae, umbilical cord
compression, fetal well-being, and labor. There is no
consensus on the optimal frequency of assessment, but
an acceptable strategy would include periodic ultraso-
nographic monitoring of fetal growth and periodic fetal
heart rate monitoring. A temperature elevation may indi-
cate intrauterine infection. Prompt diagnosis of chorio-
amnionitis in preterm pregnancy requires a high index
of suspicion because early signs and symptoms may
be subtle. In the absence of fever, other clinical criteria
have variable sensitivity and specificity for diagnosing
infection. Serial monitoring of leukocyte counts and
other markers of inflammation have not been proved to
be useful and are nonspecific when there is no clinical
evidence of infection, especially if antenatal corticoste-
roids have been administered (58). Specific management
considerations regarding tocolytics, corticosteroids, anti-
biotics, magnesium sulfate, and timing of delivery are
discussed in detail as follows.
Should tocolytics be considered for patients
with preterm PROM?
The use of tocolysis in the setting of preterm PROM is
controversial and practice patterns among specialists
vary widely (59). There are insufficient data to support
or refute the use of prophylactic tocolysis in the setting
of preterm PROM. A meta-analysis of eight trials that
included 408 women is of limited use because women
were only treated in two of the trials (60, 61) with
latency antibiotics and corticosteroids, both of which
have become part of standard management (62). The use
of tocolysis was associated with a longer latency period
and a lower risk of delivery within 48 hours but also was
associated with a high risk of chorioamnionitis in preg-
nancies before 34 0/7 weeks of gestation. In summary,
prophylactic tocolysis may be associated with a prolon-
gation of pregnancy and an increased risk of chorioam-
nionitis without significant maternal or neonatal benefit,
although its use has not been evaluated adequately with
latency antibiotics and corticosteroids. In the setting of
ruptured membranes with active labor, therapeutic tocol-
ysis has not been shown to prolong latency or improve
neonatal outcomes. Therefore, therapeutic tocolysis is
not recommended (63).
VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin
Premature Rupture of Membranes 923
Should antibiotics be administered to patients
with preterm PROM?
Administration of broad-spectrum antibiotics prolongs
pregnancy, reduces maternal and neonatal infections, and
reduces gestational age-dependent morbidity (16, 74, 75).
The optimal antibiotic regimen is unclear because mul-
tiple regimens have demonstrated benefit. Based on avail-
able information, in order to reduce maternal and neonatal
infections and gestational-age dependent morbidity, a
7-day course of therapy with a combination of intravenous
ampicillin and erythromycin followed by oral amoxicil-
lin and erythromycin is recommended during expectant
management of women with preterm PROM who are
less than 34 0/7 weeks of gestation (16, 74). The regimen
used in the Eunice Kennedy Shriver National Institute of
Child Health and Human Development Maternal–Fetal
Medicine Units Network trial was intravenous ampicillin
(2 g every 6 hours) and erythromycin (250 mg every 6
hours) for 48 hours followed by oral amoxicillin (250 mg
every 8 hours) and erythromycin base (333 mg every
8 hours) (75). The use of amoxicillin–clavulanic acid
has been associated with increased rates of necrotiz-
ing enterocolitis and it is not recommended (16, 74).
Although there are no well-studied alternative regimens
for women allergic to β-lactam antibiotics, it may be rea-
sonable to administer erythromycin alone. Women with
preterm PROM and a viable fetus who are candidates for
intrapartum GBS prophylaxis should receive intrapartum
GBS prophylaxis to prevent vertical transmission regard-
less of earlier treatments (41, 76, 77).
Should preterm PROM be managed with
home care?
The outpatient management of preterm PROM with a
viable fetus has not been sufficiently studied to establish
safety and, therefore, is not recommended. Two small ran-
domized controlled trials that compared hospitalization to
home care of women with preterm PROM had insufficient
power to demonstrate a meaningful difference in outcome
because only 11–18% of the women were eligible for ante-
partum home care (78, 79). Because latency is frequently
brief, infection may present suddenly and the fetus is at
increased risk of umbilical cord compression, hospital-
ization with surveillance of the woman and her fetus is
recommended once viability has been reached.
How should a patient with preterm PROM
and a cervical cerclage be treated?
There are no prospective studies with which to guide the
care of women with preterm PROM who have a cervi-
cal cerclage. Results from retrospective studies have not
been consistent, but generally have found that cerclage
retention for more than 24 hours after preterm PROM is
associated with pregnancy prolongation (80); however,
because of the nonrandomized nature of the reports, it
is unclear how factors, such as labor or infection, con-
tributed to decisions for cerclage removal, which may
have yielded biased results. In some, but not all studies,
cerclage retention with preterm PROM has been associ-
ated with increased rates of neonatal mortality from sep-
sis, neonatal sepsis, respiratory distress syndrome, and
maternal chorioamnionitis (80, 81).
A firm recommendation whether a cerclage should
be removed after premature PROM cannot be made, and
either removal or retention is reasonable. Regardless,
if a cerclage remains in place with preterm PROM,
prolonged antibiotic prophylaxis beyond 7 days is not
recommended.
What is the optimal management of a patient
with preterm PROM and herpes simplex virus
infection or human immunodeficiency virus?
Neonatal herpes simplex virus (HSV) infection usually
results from maternal–fetal transmission during delivery.
The risk of vertical transmission with delivery in primary
HSV is reported to be between 30% and 50%, compared
with only 3% in cases of recurrent HSV (82). The litera-
ture regarding expectant management of preterm PROM
with active maternal HSV infection is limited to small
case series and case reports (83, 84). All patients were
treated with acyclovir, and cesarean delivery was per-
formed if lesions were present at the time of delivery. No
cases of vertical transmission were reported.
The risk of prematurity should be weighed against
the potential risk of neonatal HSV infection. In the set-
ting of PROM with recurrent active infection, expectant
management is recommended before 34 0/7 weeks of
gestation. Herpes simplex virus therapy should be initi-
ated, and corticosteroids, antibiotics, and magnesium
sulfate for neuroprotection should be provided as clini-
cally indicated. If active disease or prodromal symptoms
are present at the onset of labor or when delivery is indi-
cated, cesarean delivery is recommended.
Optimal management of preterm PROM in the
setting of primary HSV infection is less clear because
of the increased risk of vertical transmission. Herpes
simplex virus therapy is recommended, and if lesions
are present at the time of delivery, cesarean delivery is
recommended.
The optimal management of the patient with HIV
and preterm PROM is also uncertain because there are
no adequate data from patients with prolonged rupture
of the membranes. Early observations showed that the
924 Practice Bulletin Premature Rupture of Membranes
OBSTETRICS & GYNECOLOGY
duration of membrane rupture in labor correlated with
risk of transmission to the newborn (85), but current data
suggest that the duration of membrane rupture is not cor-
related with risk of vertical transmission in patients who
receive highly-active antiretroviral therapy, have a low
viral load, and receive antepartum and intrapartum zid-
ovudine (86). Also, a series of 10 patients with preterm
PROM who were managed expectantly while receiving
antiretroviral therapy, had no cases of HIV transmission
to the newborn despite viral loads as high as 23,000 cop-
ies per mL; the latent periods ranged from 4 hours to 4
days in this series, and all patients were delivered by
cesarean (87).
The management of patients with HIV infection who
have preterm PROM should be individualized, with con-
sideration of factors, including gestational age, current
antiretroviral regimen, and viral load. In cases where the
gestational age is very early, the patient is being treated
with antiretroviral medications, and the viral load is low,
a period of expectant management may be appropriate.
In all cases, the patient should be managed in consulta-
tion with a physician with expertise in management of
HIV in pregnancy. Furthermore, standard antepartum
and intrapartum treatment guidelines should be followed
and management choices should be fully discussed with
the patient (88).
How does care differ for patients with PROM
that occurs before neonatal viability?
Women presenting with PROM before neonatal viability
should be counseled regarding the risks and benefits
of expectant management versus immediate delivery.
Counseling should include a realistic appraisal of neo-
natal outcomes. Immediate delivery should be offered.
Attempts should be made to provide parents with the
most current and accurate information possible (89).
If the patient opts for expectant management and is
clinically stable with no evidence of infection, outpatient
surveillance can be considered. Precautions should be
reviewed with the patient and she should come to the
hospital if she develops symptoms of infection, labor, or
abruptio placentae. It may be useful to instruct patients
to monitor temperatures. Typically, women with previ-
able PROM who have been cared for as outpatients are
admitted to the hospital once the pregnancy has reached
viability.
Administration of antenatal corticosteroids and
latency antibiotics for fetal maturation upon reach-
ing viability is appropriate given that early delivery
remains likely. Multiple ultrasonographic methods (such
as thoracic measurements and ratios, flow velocities in
pulmonary vessels, and three-dimensional estimations of
lung volume) have been studied to evaluate pulmonary
development in the antepartum period, but all are of lim-
ited accuracy and cannot be considered sufficiently reli-
able for clinical management (30). There is insufficient
evidence to support the use of latency antibiotics with
PROM before viability. Similarly, there is no evidence
to support the use of tocolytics in the setting of previable
preterm PROM, and in this setting, tocolytics should not
be used.
What is the expected outcome of PROM after
second-trimester amniocentesis?
In studies of women undergoing second-trimester amni-
ocentesis for prenatal diagnosis of genetic disorders, the
risk of PROM is approximately 1% (90, 91). In contrast
to patients with spontaneous PROM in the second
trimester, reaccumulation of normal amniotic fluid vol-
ume and favorable outcomes are expected. In one series
of 11 patients with PROM after genetic amniocentesis,
there was one previable pregnancy loss, reaccumula-
tion of normal amniotic fluid occurred within 1 month
in 72% of patients, and the perinatal survival rate was
91% (90).
After appropriate counseling, patients with PROM
after genetic amniocentesis typically are managed expec-
tantly as outpatients. Precautions regarding symptoms
of chorioamnionitis and miscarriage should be given.
Regular follow-up visits with ultrasonographic examina-
tions to assess amniotic fluid volume are recommended.
How should a patient with a history of
preterm PROM be managed in future
pregnancies?
Patients with prior preterm PROM have an increased
risk of recurrent PROM and preterm birth, and a detailed
medical history should be taken. However, there are few
studies that examine interventions to prevent recurrent
PROM. Patients with a history of preterm PROM were
included in studies of progesterone supplementation for
preterm birth recurrence reduction, but most studies did
not report the specific proportion of women with PROM
in the study group or separately analyze results in those
patients (92, 93). However, given the potential benefit
of progesterone therapy, women with a single gestation
and a prior spontaneous preterm birth (due to either labor
with intact membranes or PROM) should be offered
progesterone supplementation starting at 16 weeks to 24
weeks of gestation to reduce the risk of recurrent sponta-
neous preterm birth.
Although vaginal ultrasonographic measurement of
the cervix is a safe and reliable means of evaluating the risk
of preterm birth related to cervical length, there have been
VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin
Premature Rupture of Membranes 925
no well-designed trials of cervical surveillance in women
with a history of PROM. Similar to the progesterone
studies, women with prior PROM were included in trials
that evaluated cervical assessment, vaginal progesterone,
and cerclage but their specific data were not reported
(94, 95). Thus, as with women with spontaneous preterm
births, consideration can be given to transvaginal cervi-
cal length screening. Cerclage placement is associated
with significant decreases in preterm birth outcomes,
offers perinatal benefits, and may be considered in
women with the following combination of history and
ultrasound findings: a current singleton pregnancy,
prior spontaneous preterm birth at less than 34 weeks of
gestation, and short cervical length (less than 25 mm)
before 24 weeks of gestation (96). There are no data on
which to base a recommendation regarding the optimal
gestational age for initiating surveillance or frequency
of monitoring.
Summary of
Recommendations and
Conclusions
The following recommendations are based on
good and consistent scientific evidence (Level A):
Patients with PROM before 34 0/7 weeks of gesta-
tion should be managed expectantly if no maternal
or fetal contraindications exist.
To reduce maternal and neonatal infections and
gestational-age dependent morbidity, a 7-day course
of therapy with a combination of erythromycin and
ampicillin or amoxicillin is recommended during
expectant management of women with preterm
PROM who are less than 34 0/7 weeks of gestation.
Women with preterm PROM and a viable fetus
who are candidates for intrapartum GBS prophy-
laxis should receive intrapartum GBS prophylaxis
to prevent vertical transmission regardless of earlier
treatments.
A single course of corticosteroids is recommended
for pregnant women between 24 0/7 weeks and 34
0/7 weeks of gestation who are at risk of preterm
delivery.
Women with preterm PROM before 32 0/7 weeks of
gestation who are thought to be at risk of imminent
delivery should be considered candidates for fetal
neuroprotective treatment with intravenous magne-
sium sulfate.
The following recommendations and conclusions
are based on limited and inconsistent scientific
evidence (Level B):
For women with PROM at 37 0/7 weeks of gesta-
tion or more, if spontaneous labor does not occur
near the time of presentation in those who do not
have contraindications to labor, labor should be
induced.
At 34 0/7 weeks or greater gestation, delivery
is recommended for all women with ruptured
membranes.
In the setting of ruptured membranes with active
labor, therapeutic tocolysis has not been shown to
prolong latency or improve neonatal outcomes.
Therefore, therapeutic tocolysis is not recommended.
The following conclusion is based primarily on
consensus and expert opinion (Level C):
The outpatient management of preterm PROM with
a viable fetus has not been sufficiently studied to
establish safety and, therefore, is not recommended.
Proposed Performance
Measure
The percentage of expectantly managed patients with
preterm PROM (up to 34 0/7 weeks of gestation) that
receive latency antibiotics and corticosteroids
References
1. Martin JA, Hamilton BE, Ventura SJ, Osterman MJ,
Wilson EC, Mathews TJ. Births: final data for 2010. Natl
Vital Stat Rep 2012;61(1):1–71. (Level II-3)
2. Mathews TJ, MacDorman MF. Infant mortality statistics
from the 2006 period linked birth/infant death data set.
Natl Vital Stat Rep 2010;58:1–31. (Level II-3) [PubMed]
3. Waters TP, Mercer B. Preterm PROM: prediction, pre-
vention, principles. Clin Obstet Gynecol 2011;54:307–12.
(Level III) [PubMed]
4. Moore RM, Mansour JM, Redline RW, Mercer BM,
Moore JJ. The physiology of fetal membrane rupture:
insight gained from the determination of physical proper-
ties. Placenta 2006;27:1037–51. (Level III) [PubMed]
5. Mercer BM. Preterm premature rupture of the mem-
branes. Obstet Gynecol 2003;101:178–93. (Level III)
[PubMed] [Obstetrics & Gynecology]
6. Garite TJ, Freeman RK. Chorioamnionitis in the preterm
gestation. Obstet Gynecol 1982;59:539–45. (Level II-3)
[PubMed] [Obstetrics & Gynecology]
http://www.ncbi.nlm.nih.gov/pubmed/20815136
http://www.ncbi.nlm.nih.gov/pubmed/21508700
http://www.ncbi.nlm.nih.gov/pubmed/16516962
http://www.ncbi.nlm.nih.gov/pubmed/12517665
http://journals.lww.com/greenjournal/Fulltext/2003/01000/Prete
rm_Premature_Rupture_of_the_Membranes.33.aspx
http://www.ncbi.nlm.nih.gov/pubmed/7070724
http://journals.lww.com/greenjournal/Abstract/1982/05000/Chor
ioamnionitis_in_the_Preterm_Gestation.1.aspx
926 Practice Bulletin Premature Rupture of Membranes
OBSTETRICS & GYNECOLOGY
7. Mercer BM, Goldenberg RL, Moawad AH, Meis PJ,
Iams JD, Das AF, et al. The preterm prediction study:
effect of gestational age and cause of preterm birth on
subsequent obstetric outcome. National Institute of Child
Health and Human Development Maternal-Fetal Medicine
Units Network. Am J Obstet Gynecol 1999;181:1216–21.
(Level II-2) [PubMed]
8. Asrat T, Lewis DF, Garite TJ, Major CA, Nageotte MP,
Towers CV, et al. Rate of recurrence of preterm prema-
ture rupture of membranes in consecutive pregnancies.
Am J Obstet Gynecol 1991;165:1111–5. (Level II-2)
[PubMed]
9. Mercer BM, Goldenberg RL, Meis PJ, Moawad AH,
Shellhaas C, Das A, et al. The Preterm Prediction
Study: prediction of preterm premature rupture of mem-
branes through clinical findings and ancillary testing.
The National Institute of Child Health and Human
Development Maternal-Fetal Medicine Units Network.
Am J Obstet Gynecol 2000;183:738–45. (Level II-2)
[PubMed] [Full Text]
10. Harger JH, Hsing AW, Tuomala RE, Gibbs RS, Mead PB,
Eschenbach DA, et al. Risk factors for preterm premature
rupture of fetal membranes: a multicenter case-control
study. Am J Obstet Gynecol 1990;163:130–7. (Level II-2)
[PubMed]
11. Berkowitz GS, Blackmore-Prince C, Lapinski RH, Savitz
DA. Risk factors for preterm birth subtypes. Epidemiology
1998;9:279–85. (Level II-3) [PubMed]
12. Treadwell MC, Bronsteen RA, Bottoms SF. Prognostic
factors and complication rates for cervical cerclage: a
review of 482 cases. Am J Obstet Gynecol 1991;165:
555–8. (Level II-3) [PubMed]
13. Hannah ME, Ohlsson A, Farine D, Hewson SA, Hodnett
ED, Myhr TL, et al. Induction of labor compared with
expectant management for prelabor rupture of the mem-
branes at term. TERMPROM Study Group. N Engl J Med
1996;334:1005–10. (Level I) [PubMed] [Full Text]
14. Melamed N, Hadar E, Ben-Haroush A, Kaplan B, Yogev Y.
Factors affecting the duration of the latency period in
preterm premature rupture of membranes. J Matern Fetal
Neonatal Med 2009;22:1051– 6. (Level II-3) [PubMed]
[Full Text]
15. Johnson JW, Egerman RS, Moorhead J. Cases with
ruptured membranes that “reseal”. Am J Obstet Gynecol
1990;163:1024–30; discussion 1030–2. (Level II-2)
[PubMed]
16. Kenyon S, Boulvain M, Neilson JP. Antibiotics for pre-
term rupture of membranes. Cochrane Database of
Systematic Reviews 2010, Issue 8. Art. No.: CD001058.
DOI: 10.1002/14651858.CD001058.pub2. (Meta-analysis)
[PubMed] [Full Text]
17. Beydoun SN, Yasin SY. Premature rupture of the mem-
branes before 28 weeks: conservative management. Am J
Obstet Gynecol 1986;155:471–9. (Level III) [PubMed]
18. Major CA, de Veciana M, Lewis DF, Morgan MA. Preterm
premature rupture of membranes and abruptio placentae:
is there an association between these pregnancy complica-
tions? Am J Obstet Gynecol 1995;172:672–6. (Level II-3)
[PubMed] [Full Text]
19. Ananth CV, Oyelese Y, Srinivas N, Yeo L, Vintzileos
AM. Preterm premature rupture of membranes, intra-
uterine infection, and oligohydramnios: risk factors for
placental abruption. Obstet Gynecol 2004;104:71–7.
(Level II-3) [PubMed] [Obstetrics & Gynecology]
20. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA,
Stoll BJ, et al. Very low birth weight outcomes of the
National Institute of Child health and human develop-
ment neonatal research network, January 1995 through
December 1996. NICHD Neonatal Research Network.
Pediatrics 2001;107:E1. (Level II-3) [PubMed] [Full
Text]
21. Spinillo A, Capuzzo E, Stronati M, Ometto A, Orcesi S,
Fazzi E. Effect of preterm premature rupture of mem-
branes on neurodevelopmental outcome: follow up at
two years of age. Br J Obstet Gynaecol 1995;102:882–7.
(Level II-2) [PubMed]
22. Yoon BH, Romero R, Park JS, Kim CJ, Kim SH, Choi JH,
et al. Fetal exposure to an intra-amniotic inflammation
and the development of cerebral palsy at the age of
three years. Am J Obstet Gynecol 2000;182:675–81.
(Level II-2) [PubMed]
23. Locatelli A, Ghidini A, Paterlini G, Patane L, Doria V,
Zorloni C, et al. Gestational age at preterm premature
rupture of membranes: a risk factor for neonatal white
matter damage. Am J Obstet Gynecol 2005;193:947–51.
(Level II-3) [PubMed] [Full Text]
24. Mercer BM, Arheart KL. Antimicrobial therapy in
expectant management of preterm premature rupture of
the membranes [published erratum appears in Lancet
1996;347:410]. Lancet 1995;346:1271–9. (Meta-analysis)
[PubMed] [Full Text]
25. Manuck TA, Eller AG, Esplin MS, Stoddard GJ, Varner
MW, Silver RM. Outcomes of expectantly managed pre-
term premature rupture of membranes occurring before
24 weeks of gestation. Obstet Gynecol 2009;114:29–37.
(Level II-3) [PubMed] [Obstetrics & Gynecology]
26. Waters TP, Mercer BM. The management of preterm pre-
mature rupture of the membranes near the limit of fetal via-
bility. Am J Obstet Gynecol 2009;201:230–40. (Level III)
[PubMed] [Full Text]
27. Schucker JL, Mercer BM. Midtrimester premature rupture
of the membranes. Semin Perinatol 1996;20:389–400.
(Level III) [PubMed]
28. Muris C, Girard B, Creveuil C, Durin L, Herlicoviez M,
Dreyfus M. Management of premature rupture of mem-
branes before 25 weeks. Eur J Obstet Gynecol Reprod
Biol 2007;131:163–8. (Level III) [PubMed] [Full Text]
29. Farooqi A, Holmgren PA, Engberg S, Serenius F. Survival
and 2-year outcome with expectant management of
second-trimester rupture of membranes. Obstet Gynecol
1998;92:895–901. (Level II-3) [PubMed] [Obstetrics &
Gynecology]
30. van Teeffelen AS, van der Ham DP, Oei SG, Porath MM,
Willekes C, Mol BW. The accuracy of clinical parameters
in the prediction of perinatal pulmonary hypoplasia sec-
ondary to midtrimester prelabour rupture of fetal mem-
branes: a meta-analysis. Eur J Obstet Gynecol Reprod
http://www.ncbi.nlm.nih.gov/pubmed/10561648
http://www.ncbi.nlm.nih.gov/pubmed/1951524
http://www.ncbi.nlm.nih.gov/pubmed/10992202
http://www.sciencedirect.com/science/article/pii/S00029378006
45696/pdf?md5=3ce6096f67352b916265c86130581587&pid=1-
s2.0-S0002937800645696-main.pdf
http://www.ncbi.nlm.nih.gov/pubmed/2197863
http://www.ncbi.nlm.nih.gov/pubmed/9583419
http://www.ncbi.nlm.nih.gov/pubmed/1892180
http://www.ncbi.nlm.nih.gov/pubmed/8598837
http://www.nejm.org/doi/full/10.1056/NEJM199604183341601#
t=article
http://www.ncbi.nlm.nih.gov/pubmed/19900043
http://informahealthcare.com/doi/full/10.3109/14767050903019
650
http://www.ncbi.nlm.nih.gov/pubmed/2206055
http://www.ncbi.nlm.nih.gov/pubmed/20687063
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001058
.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/3752169
http://www.ncbi.nlm.nih.gov/pubmed/7856704
http://www.sciencedirect.com/science/article/pii/000293789590
591X/pdf?md5=09506f1981dadfa14ebf88302236e832&pid=1-
s2.0-000293789590591X-main.pdf
http://www.ncbi.nlm.nih.gov/pubmed/15229003
http://journals.lww.com/greenjournal/Fulltext/2004/07000/Prete
rm_Premature_Rupture_of_Membranes,.12.aspx
http://www.ncbi.nlm.nih.gov/pubmed/11134465
http://pediatrics.aappublications.org/content/107/1/e1.long
http://pediatrics.aappublications.org/content/107/1/e1.long
http://www.ncbi.nlm.nih.gov/pubmed/8534623
http://www.ncbi.nlm.nih.gov/pubmed/10739529
http://www.ncbi.nlm.nih.gov/pubmed/16157092
http://www.sciencedirect.com/science/article/pii/S00029378050
08835
http://www.ncbi.nlm.nih.gov/pubmed/7475723
http://www.sciencedirect.com/science/article/pii/S01406736959
1868X/pdf?md5=351cc9331e911244571ff1f5f1bd7d87&pid=1-
s2.0-S014067369591868X-main.pdf
http://www.ncbi.nlm.nih.gov/pubmed/19546755
http://journals.lww.com/greenjournal/Fulltext/2009/07000/Outc
omes_of_Expectantly_Managed_Preterm_Premature.7.aspx
http://www.ncbi.nlm.nih.gov/pubmed/19733274
http://www.sciencedirect.com/science/article/pii/S00029378090
06930
http://www.ncbi.nlm.nih.gov/pubmed/8912993
http://www.ncbi.nlm.nih.gov/pubmed/16846673
http://www.sciencedirect.com/science/article/pii/S03012115060
02843
http://www.ncbi.nlm.nih.gov/pubmed/9840545
http://journals.lww.com/greenjournal/Abstract/1998/12000/Surv
ival_and_2_Year_Outcome_With_Expectant.1.aspx
http://journals.lww.com/greenjournal/Abstract/1998/12000/Surv
ival_and_2_Year_Outcome_With_Expectant.1.aspx
VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin
Premature Rupture of Membranes 927
Biol 2010;148:3–12. (Meta-analysis) [PubMed] [Full
Text]
31. van Teeffelen AS, Van Der Heijden J, Oei SG, Porath MM,
Willekes C, Opmeer B, et al. Accuracy of imaging
parameters in the prediction of lethal pulmonary hypo-
plasia secondary to mid-trimester prelabor rupture of
fetal membranes: a systematic review and meta-analy-
sis. Ultrasound Obstet Gynecol 2012;39:495–9. (Meta-
analysis) [PubMed] [Full Text]
32. Blott M, Greenough A. Neonatal outcome after prolonged
rupture of the membranes starting in the second trimester.
Arch Dis Child 1988;63:1146–50. (Level III) [PubMed]
[Full Text]
33. Alexander JM, Mercer BM, Miodovnik M, Thurnau GR,
Goldenberg RL, Das AF, et al. The impact of digital
cervical examination on expectantly managed preterm
rupture of membranes. Am J Obstet Gynecol 2000;183:
1003–7. (Level II-2) [PubMed] [Full Text]
34. Munson LA, Graham A, Koos BJ, Valenzuela GJ. Is there
a need for digital examination in patients with spontane-
ous rupture of the membranes? Am J Obstet Gynecol
1985;153:562–3. (Level III) [PubMed]
35. Eriksen NL, Parisi VM, Daoust S, Flamm B, Garite
TJ, Cox SM. Fetal fibronectin: a method for detecting
the presence of amniotic fluid. Obstet Gynecol 1992;80:
451–4. (Level II-2) [PubMed] [Obstetrics & Gynecology]
36. Lee SE, Park JS, Norwitz ER, Kim KW, Park HS, Jun JK.
Measurement of placental alpha-microglobulin-1 in cer-
vicovaginal discharge to diagnose rupture of membranes.
Obstet Gynecol 2007;109:634–40. (Level II-3) [PubMed]
[Obstetrics & Gynecology]
37. Cousins LM, Smok DP, Lovett SM, Poeltler DM.
AmniSure placental alpha microglobulin-1 rapid immu-
noassay versus standard diagnostic methods for detec-
tion of rupture of membranes. Am J Perinatol 2005;22:
317–20. (Level II-3) [PubMed] [Full Text]
38. Lee SM, Lee J, Seong HS, Lee SE, Park JS, Romero R, et
al.
The clinical significance of a positive Amnisure test
in women with term labor with intact membranes. J
Matern Fetal Neonatal Med 2009;22:305–10. (Level II-3)
[PubMed] [Full Text]
39. Lee SM, Romero R, Park JW, Kim SM, Park CW,
Korzeniewski SJ, et al. The clinical significance of a
positive Amnisure test in women with preterm labor and
intact membranes. J Matern Fetal Neonatal Med 2012;25:
1690–8. (Level II-2) [PubMed] [Full Text]
40. Smith CV, Greenspoon J, Phelan JP, Platt LD. Clinical
utility of the nonstress test in the conservative manage-
ment of women with preterm spontaneous premature
rupture of the membranes. J Reprod Med 1987;32:1–4.
(Level II-3) [PubMed]
41. Verani JR, McGee L, Schrag SJ. Prevention of perinatal
group B streptococcal disease––revised guidelines from
CDC, 2010. Division of Bacterial Diseases, National
Center for Immunization and Respiratory Diseases,
Centers for Disease Control and Prevention (CDC).
MMWR Recomm Rep 2010;59(RR-10):1–36. (Level I)
[PubMed] [Full Text]
42. Dare MR, Middleton P, Crowther CA, Flenady V,
Varatharaju B. Planned early birth versus expectant man-
agement (waiting) for prelabour rupture of membranes
at term (37 weeks or more). Cochrane Database of
Systematic Reviews 2006, Issue 1. Art. No.: CD005302.
DOI: 10.1002/14651858.CD005302.pub2. (Meta-analysis)
[PubMed] [Full Text]
43. Flenady V, King JF. Antibiotics for prelabour rupture
of membranes at or near term. Cochrane Database of
Systematic Reviews 2002, Issue 3. Art. No.: CD001807.
DOI: 10.1002/14651858.CD001807. (Meta-analysis)
[PubMed] [Full Text]
44. Ovalle A, Martinez MA, Kakarieka E, Gomez R, Rubio R,
Valderrama O, et al. Antibiotic administration in patients
with preterm premature rupture of membranes reduces
the rate of histological chorioamnionitis: a prospective,
randomized, controlled study. J Matern Fetal Neonatal
Med 2002;12:35–41. (Level I) [PubMed] [Full Text]
45. Cararach V, Botet F, Sentis J, Almirall R, Perez-Picanol E.
Administration of antibiotics to patients with rupture of
membranes at term: a prospective, randomized, multicen-
tric study. Collaborative Group on PROM. Acta Obstet
Gynecol Scand 1998;77:298–302. (Level I) [PubMed]
[Full Text]
46. Rouse DJ, Weiner SJ, Bloom SL, Varner MW, Spong CY,
Ramin SM, et al. Failed labor induction: toward an objec-
tive diagnosis. Eunice Kennedy Shriver National Institute
of Child Health and Human Development (NICHD)
Maternal-Fetal Medicine Units Network (MFMU).
Obstet Gynecol 2011;117:267–72. (Level III) [PubMed]
[Obstetrics & Gynecology]
47. Rouse DJ, Owen J, Hauth JC. Criteria for failed labor
induction: prospective evaluation of a standardized
protocol. Obstet Gynecol 2000;96:671–7. (Level II-3)
[PubMed] [Obstetrics & Gynecology]
48. Simon CE, Grobman WA. When Has an Induction
Failed? Obstet Gynecol 2005;105:705–9. (Level II-2)
[PubMed] [Obstetrics & Gynecology]
49. Buchanan SL, Crowther CA, Levett KM, Middleton P,
Morris J. Planned early birth versus expectant management
for women with preterm prelabour rupture of membranes
prior to 37 weeks’ gestation for improving pregnancy
outcome. Cochrane Database of Systematic Reviews
2010, Issue 3. Art. No.: CD004735. DOI: 10.1002/
14651858.CD004735.pub3. (Meta-analysis) [PubMed]
[Full Text]
50. van der Ham DP, van der Heyden JL, Opmeer BC,
Mulder AL, Moonen RM, van Beek JH, et al. Management
of late-preterm premature rupture of membranes: the
PPROMEXIL-2 trial. Am J Obstet Gynecol 2012;207:276.
e1–276.10. (Level I) [PubMed] [Full Text]
51. van der Ham DP, Vijgen SM, Nijhuis JG, van Beek JJ,
Opmeer BC, Mulder AL, et al. Induction of labor versus
expectant management in women with preterm prelabor
rupture of membranes between 34 and 37 weeks: a ran-
domized controlled trial. PPROMEXIL trial group. PLoS
Med 2012;9:e1001208. (Level I) [PubMed] [Full Text]
52. Naef RW 3rd, Allbert JR, Ross EL, Weber BM, Martin
RW, Morrison JC. Premature rupture of membranes at
http://www.ncbi.nlm.nih.gov/pubmed/19892458
http://www.sciencedirect.com/science/article/pii/S03012115090
05934
http://www.sciencedirect.com/science/article/pii/S03012115090
05934
http://www.ncbi.nlm.nih.gov/pubmed/21793083
http://onlinelibrary.wiley.com/doi/10.1002/uog.10047/full
http://www.ncbi.nlm.nih.gov/pubmed/3196069
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1590218/pdf/arc
hdisch00903-0034.pdf
http://www.ncbi.nlm.nih.gov/pubmed/11035354
http://www.sciencedirect.com/science/article/pii/S00029378008
63036/pdf?md5=8bee388b8dc5369c41a3f7d6ede65b13&pid=1-
s2.0-S0002937800863036-main.pdf
http://www.ncbi.nlm.nih.gov/pubmed/4061518
http://www.ncbi.nlm.nih.gov/pubmed/1495705
http://journals.lww.com/greenjournal/Abstract/1992/09000/Fetal
_Fibronectin__A_Method_for_Detecting_the.28.aspx
http://www.ncbi.nlm.nih.gov/pubmed/17329514
http://journals.lww.com/greenjournal/Fulltext/2007/03000/Meas
urement_of_Placental_Alpha_Microglobulin_1_in.9.aspx
http://www.ncbi.nlm.nih.gov/pubmed/16118720
https://www.thieme-connect.com/ejournals/html/10.1055/s-
2005-870896
http://www.ncbi.nlm.nih.gov/pubmed/19350444
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744034/
http://www.ncbi.nlm.nih.gov/pubmed/22280400
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422421/
http://www.ncbi.nlm.nih.gov/pubmed/3560057
http://www.ncbi.nlm.nih.gov/pubmed/21088663
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5910a1.htm
http://www.ncbi.nlm.nih.gov/pubmed/16437525
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005302
.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/12137635
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001807
/full
http://www.ncbi.nlm.nih.gov/pubmed/12422907
http://informahealthcare.com/doi/pdf/10.1080/jmf.12.1.35.41
http://www.ncbi.nlm.nih.gov/pubmed/9580172
http://onlinelibrary.wiley.com/doi/10.1034/j.1600-
0412.1998.770308.x/pdf
http://www.ncbi.nlm.nih.gov/pubmed/21252738
http://journals.lww.com/greenjournal/Fulltext/2011/02000/Faile
d_Labor_Induction__Toward_an_Objective.10.aspx
http://www.ncbi.nlm.nih.gov/pubmed/11042299
http://journals.lww.com/greenjournal/Fulltext/2000/11000/Crite
ria_for_Failed_Labor_Induction__Prospective.6.aspx
http://www.ncbi.nlm.nih.gov/pubmed/15802394
http://journals.lww.com/greenjournal/Fulltext/2005/04000/When
_Has_an_Induction_Failed_.5.aspx
http://www.ncbi.nlm.nih.gov/pubmed/20238332
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004735
.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/22901981
http://www.sciencedirect.com/science/article/pii/S00029378120
07764
http://www.ncbi.nlm.nih.gov/pubmed/22545024
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335867/
928 Practice Bulletin Premature Rupture of Membranes
OBSTETRICS & GYNECOLOGY
34 to 37 weeks’ gestation: aggressive versus conservative
management. Am J Obstet Gynecol 1998;178:126–30.
(Level I) [PubMed]
53. Mercer BM, Crocker LG, Boe NM, Sibai BM. Induction
versus expectant management in premature rupture of
the membranes with mature amniotic fluid at 32 to 36
weeks: a randomized trial. Am J Obstet Gynecol 1993;169:
775–82. (Level I) [PubMed]
54. Teune MJ, Bakhuizen S, Gyamfi Bannerman C, Opmeer
BC, van Kaam AH, van Wassenaer AG, et al. A sys-
tematic review of severe morbidity in infants born late
preterm. Am J Obstet Gynecol 2011;205:374.e1–374.e9.
(Meta-analysis) [PubMed] [Full Text]
55. McGowan JE, Alderdice FA, Holmes VA, Johnston L.
Early childhood development of late-preterm infants: a
systematic review. Pediatrics 2011;127:1111–24. (Level
III) [PubMed] [Full Text]
56. Melamed N, Ben-Haroush A, Pardo J, Chen R, Hadar E,
Hod M, et al. Expectant management of preterm prema-
ture rupture of membranes: is it all about gestational age?
Am J Obstet Gynecol 2011;204:48.e1–48.e8. (Level II-3)
[PubMed] [Full Text]
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx
LESSON 12 Paying for Care and Health Information   LEA.docx

Weitere ähnliche Inhalte

Ähnlich wie LESSON 12 Paying for Care and Health Information LEA.docx

Mdmc research project
Mdmc research projectMdmc research project
Mdmc research project
jacbudet
 
Medically Complex Pregnancies and Early BreastfeedingBehavio.docx
Medically Complex Pregnancies and Early BreastfeedingBehavio.docxMedically Complex Pregnancies and Early BreastfeedingBehavio.docx
Medically Complex Pregnancies and Early BreastfeedingBehavio.docx
ARIV4
 
Interventions In Primary Care To Promote Breastfeeding An Evidence Review For...
Interventions In Primary Care To Promote Breastfeeding An Evidence Review For...Interventions In Primary Care To Promote Breastfeeding An Evidence Review For...
Interventions In Primary Care To Promote Breastfeeding An Evidence Review For...
Biblioteca Virtual
 
Mothers And Clinicians Perspectives On Breastfeeding Counseling During Routin...
Mothers And Clinicians Perspectives On Breastfeeding Counseling During Routin...Mothers And Clinicians Perspectives On Breastfeeding Counseling During Routin...
Mothers And Clinicians Perspectives On Breastfeeding Counseling During Routin...
Biblioteca Virtual
 
Acog 2011 acs for flm
Acog 2011 acs for flmAcog 2011 acs for flm
Acog 2011 acs for flm
Asha Reddy
 
perineal outcome after restrictive use of episiotomy
perineal outcome after restrictive use of episiotomyperineal outcome after restrictive use of episiotomy
perineal outcome after restrictive use of episiotomy
arbin joshi
 
Pediatric Nurses’ Knowledge and Practices Regarding Nursing Management of Pre...
Pediatric Nurses’ Knowledge and Practices Regarding Nursing Management of Pre...Pediatric Nurses’ Knowledge and Practices Regarding Nursing Management of Pre...
Pediatric Nurses’ Knowledge and Practices Regarding Nursing Management of Pre...
paperpublications3
 
Fetal monitoring workshop 2008
Fetal monitoring workshop 2008Fetal monitoring workshop 2008
Fetal monitoring workshop 2008
jenniefer
 
Why Do Women Stop Breastfeeding Findings From The Pregnancy Risk
Why Do Women Stop Breastfeeding Findings From The Pregnancy RiskWhy Do Women Stop Breastfeeding Findings From The Pregnancy Risk
Why Do Women Stop Breastfeeding Findings From The Pregnancy Risk
Biblioteca Virtual
 

Ähnlich wie LESSON 12 Paying for Care and Health Information LEA.docx (20)

628362
628362628362
628362
 
IJMPR43109-477-481.docx
IJMPR43109-477-481.docxIJMPR43109-477-481.docx
IJMPR43109-477-481.docx
 
Mdmc research project
Mdmc research projectMdmc research project
Mdmc research project
 
Medically Complex Pregnancies and Early BreastfeedingBehavio.docx
Medically Complex Pregnancies and Early BreastfeedingBehavio.docxMedically Complex Pregnancies and Early BreastfeedingBehavio.docx
Medically Complex Pregnancies and Early BreastfeedingBehavio.docx
 
Interventions In Primary Care To Promote Breastfeeding An Evidence Review For...
Interventions In Primary Care To Promote Breastfeeding An Evidence Review For...Interventions In Primary Care To Promote Breastfeeding An Evidence Review For...
Interventions In Primary Care To Promote Breastfeeding An Evidence Review For...
 
American Journal of Anesthesia & Clinical Research
American Journal of Anesthesia & Clinical ResearchAmerican Journal of Anesthesia & Clinical Research
American Journal of Anesthesia & Clinical Research
 
American Journal of Urology Research
American Journal of Urology ResearchAmerican Journal of Urology Research
American Journal of Urology Research
 
Probiotics 3 ecn
Probiotics 3 ecnProbiotics 3 ecn
Probiotics 3 ecn
 
The Natural History Of The Normal First Stage Of 6[1]
The Natural History Of The Normal First Stage Of 6[1]The Natural History Of The Normal First Stage Of 6[1]
The Natural History Of The Normal First Stage Of 6[1]
 
Mothers And Clinicians Perspectives On Breastfeeding Counseling During Routin...
Mothers And Clinicians Perspectives On Breastfeeding Counseling During Routin...Mothers And Clinicians Perspectives On Breastfeeding Counseling During Routin...
Mothers And Clinicians Perspectives On Breastfeeding Counseling During Routin...
 
Study of Incidence and Etiology of Prolapse at Rural Based Teaching Hospital
Study of Incidence and Etiology of Prolapse at Rural Based Teaching HospitalStudy of Incidence and Etiology of Prolapse at Rural Based Teaching Hospital
Study of Incidence and Etiology of Prolapse at Rural Based Teaching Hospital
 
Acog 2011 acs for flm
Acog 2011 acs for flmAcog 2011 acs for flm
Acog 2011 acs for flm
 
perineal outcome after restrictive use of episiotomy
perineal outcome after restrictive use of episiotomyperineal outcome after restrictive use of episiotomy
perineal outcome after restrictive use of episiotomy
 
Nurse staffing problems Discussion.docx
Nurse staffing problems Discussion.docxNurse staffing problems Discussion.docx
Nurse staffing problems Discussion.docx
 
Pediatric Nurses’ Knowledge and Practices Regarding Nursing Management of Pre...
Pediatric Nurses’ Knowledge and Practices Regarding Nursing Management of Pre...Pediatric Nurses’ Knowledge and Practices Regarding Nursing Management of Pre...
Pediatric Nurses’ Knowledge and Practices Regarding Nursing Management of Pre...
 
Evidence Based Practice_lecture 5_slides
Evidence Based Practice_lecture 5_slidesEvidence Based Practice_lecture 5_slides
Evidence Based Practice_lecture 5_slides
 
International Journal of Reproductive Medicine & Gynecology
International Journal of Reproductive Medicine & GynecologyInternational Journal of Reproductive Medicine & Gynecology
International Journal of Reproductive Medicine & Gynecology
 
Fetal monitoring workshop 2008
Fetal monitoring workshop 2008Fetal monitoring workshop 2008
Fetal monitoring workshop 2008
 
Pyramid of ANC care
Pyramid of ANC carePyramid of ANC care
Pyramid of ANC care
 
Why Do Women Stop Breastfeeding Findings From The Pregnancy Risk
Why Do Women Stop Breastfeeding Findings From The Pregnancy RiskWhy Do Women Stop Breastfeeding Findings From The Pregnancy Risk
Why Do Women Stop Breastfeeding Findings From The Pregnancy Risk
 

Mehr von SHIVA101531

Answer the following questions about this case studyClient .docx
Answer the following questions about this case studyClient .docxAnswer the following questions about this case studyClient .docx
Answer the following questions about this case studyClient .docx
SHIVA101531
 
Answer the following questions using art vocabulary and ideas from L.docx
Answer the following questions using art vocabulary and ideas from L.docxAnswer the following questions using art vocabulary and ideas from L.docx
Answer the following questions using art vocabulary and ideas from L.docx
SHIVA101531
 
Answer the following questions based on the ethnography Dancing Skel.docx
Answer the following questions based on the ethnography Dancing Skel.docxAnswer the following questions based on the ethnography Dancing Skel.docx
Answer the following questions based on the ethnography Dancing Skel.docx
SHIVA101531
 
Answer the following questions to the best of your ability1) De.docx
Answer the following questions to the best of your ability1) De.docxAnswer the following questions to the best of your ability1) De.docx
Answer the following questions to the best of your ability1) De.docx
SHIVA101531
 
Answer the bottom questions  in apa format and decent answer no shor.docx
Answer the bottom questions  in apa format and decent answer no shor.docxAnswer the bottom questions  in apa format and decent answer no shor.docx
Answer the bottom questions  in apa format and decent answer no shor.docx
SHIVA101531
 
ANSWER THE DISCUSSION QUESTION 250 WORDS MINDiscussion Q.docx
ANSWER THE DISCUSSION QUESTION 250 WORDS MINDiscussion Q.docxANSWER THE DISCUSSION QUESTION 250 WORDS MINDiscussion Q.docx
ANSWER THE DISCUSSION QUESTION 250 WORDS MINDiscussion Q.docx
SHIVA101531
 

Mehr von SHIVA101531 (20)

Answer the following questions in a minimum of 1-2 paragraphs ea.docx
Answer the following questions in a minimum of 1-2 paragraphs ea.docxAnswer the following questions in a minimum of 1-2 paragraphs ea.docx
Answer the following questions in a minimum of 1-2 paragraphs ea.docx
 
Answer the following questions using scholarly sources as references.docx
Answer the following questions using scholarly sources as references.docxAnswer the following questions using scholarly sources as references.docx
Answer the following questions using scholarly sources as references.docx
 
Answer the following questions about this case studyClient .docx
Answer the following questions about this case studyClient .docxAnswer the following questions about this case studyClient .docx
Answer the following questions about this case studyClient .docx
 
Answer the following questions using art vocabulary and ideas from L.docx
Answer the following questions using art vocabulary and ideas from L.docxAnswer the following questions using art vocabulary and ideas from L.docx
Answer the following questions using art vocabulary and ideas from L.docx
 
Answer the following questions in a total of 3 pages (900 words). My.docx
Answer the following questions in a total of 3 pages (900 words). My.docxAnswer the following questions in a total of 3 pages (900 words). My.docx
Answer the following questions in a total of 3 pages (900 words). My.docx
 
Answer the following questions No single word responses (at lea.docx
Answer the following questions No single word responses (at lea.docxAnswer the following questions No single word responses (at lea.docx
Answer the following questions No single word responses (at lea.docx
 
Answer the following questions based on the ethnography Dancing Skel.docx
Answer the following questions based on the ethnography Dancing Skel.docxAnswer the following questions based on the ethnography Dancing Skel.docx
Answer the following questions based on the ethnography Dancing Skel.docx
 
Answer the following questions to the best of your ability1) De.docx
Answer the following questions to the best of your ability1) De.docxAnswer the following questions to the best of your ability1) De.docx
Answer the following questions to the best of your ability1) De.docx
 
Answer the following questionDo you think it is necessary to .docx
Answer the following questionDo you think it is necessary to .docxAnswer the following questionDo you think it is necessary to .docx
Answer the following questionDo you think it is necessary to .docx
 
Answer the following question. Use facts and examples to support.docx
Answer the following question. Use facts and examples to support.docxAnswer the following question. Use facts and examples to support.docx
Answer the following question. Use facts and examples to support.docx
 
Answer the bottom questions  in apa format and decent answer no shor.docx
Answer the bottom questions  in apa format and decent answer no shor.docxAnswer the bottom questions  in apa format and decent answer no shor.docx
Answer the bottom questions  in apa format and decent answer no shor.docx
 
Answer the following below using the EXCEL attachment. chapter 5.docx
Answer the following below using the EXCEL attachment. chapter 5.docxAnswer the following below using the EXCEL attachment. chapter 5.docx
Answer the following below using the EXCEL attachment. chapter 5.docx
 
Answer the following prompts about A Germanic People Create a Code .docx
Answer the following prompts about A Germanic People Create a Code .docxAnswer the following prompts about A Germanic People Create a Code .docx
Answer the following prompts about A Germanic People Create a Code .docx
 
Answer the following discussion board question below minumun 25.docx
Answer the following discussion board question below minumun 25.docxAnswer the following discussion board question below minumun 25.docx
Answer the following discussion board question below minumun 25.docx
 
Answer the following questions about IT Project Management. What.docx
Answer the following questions about IT Project Management. What.docxAnswer the following questions about IT Project Management. What.docx
Answer the following questions about IT Project Management. What.docx
 
Answer the following in at least 100 words minimum each1.Of.docx
Answer the following in at least 100 words minimum each1.Of.docxAnswer the following in at least 100 words minimum each1.Of.docx
Answer the following in at least 100 words minimum each1.Of.docx
 
Answer the following questions(at least 200 words) and responses 2 p.docx
Answer the following questions(at least 200 words) and responses 2 p.docxAnswer the following questions(at least 200 words) and responses 2 p.docx
Answer the following questions(at least 200 words) and responses 2 p.docx
 
Answer the following questions in a Word document and upload it by M.docx
Answer the following questions in a Word document and upload it by M.docxAnswer the following questions in a Word document and upload it by M.docx
Answer the following questions in a Word document and upload it by M.docx
 
Answer the following questions in complete sentences. Each answer sh.docx
Answer the following questions in complete sentences. Each answer sh.docxAnswer the following questions in complete sentences. Each answer sh.docx
Answer the following questions in complete sentences. Each answer sh.docx
 
ANSWER THE DISCUSSION QUESTION 250 WORDS MINDiscussion Q.docx
ANSWER THE DISCUSSION QUESTION 250 WORDS MINDiscussion Q.docxANSWER THE DISCUSSION QUESTION 250 WORDS MINDiscussion Q.docx
ANSWER THE DISCUSSION QUESTION 250 WORDS MINDiscussion Q.docx
 

Kürzlich hochgeladen

Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
Chris Hunter
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
heathfieldcps1
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
MateoGardella
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.
MateoGardella
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
kauryashika82
 
An Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfAn Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdf
SanaAli374401
 

Kürzlich hochgeladen (20)

Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
An Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdfAn Overview of Mutual Funds Bcom Project.pdf
An Overview of Mutual Funds Bcom Project.pdf
 

LESSON 12 Paying for Care and Health Information LEA.docx

  • 1. LESSON 12 Paying for Care and Health Information LEARNING OUTCOMES _____________________________________________________ _________________________ In this lesson, you will do the following: Describe how coding, reimbursement, and billing are impacted by health information systems. READINGS The following reading assignments are for Lessons 9 through 12: Gartee Text: Chapter 4, pp. 74 - 95 Chapter 5, pp. 98 - 126
  • 2. Chapter 6, pp. 127 - 151 Chapter 9, pp. 208 - 236 Chapter 10, pp. 237 - 259 ACTIVITIES / ASSESSMENTS The following activities/assessments are for Lessons 9 through 12: 1. Read the assigned pages from the Gartee text. 2. Review the Lecture Notes, Unit 3 PowerPoint, and Voice Pod. 3. Participate in the weekly discussion question. 4. Complete the written assignment. WRITTEN ASSIGNMENTS Hospital Medicare Payment System - DRGs:
  • 3. Research how large hospitals are paid by a Medicare fee for service reimbursements (DRG’s). Include a brief history and relate how health information supports the request for a payment. PLEASE NOTE: All graded assignments for the lessons in this unit should be grouped together and submitted as ONE document using the Assignment Submission form accessed from your course homepage or http://www.sjcme.edu/gps/assignments. All activities/assignments for this unit should be as follows: 1. Should include a cover sheet for each assignment stating the following: 2. Each individual assignment number and copy of the assignment directions should be included in the submission as the starting header of each lesson.
  • 4. 3. Carefully check grammar and spelling. 4. Use APA format for any research or sources that are being used or quoted. 5. Email the instructor if you have questions regarding the assignments. http://www.sjcme.edu/gps/assignments g Research www.AJOG.org O B S T E T R I C S Preterm premature rupture of membranes >32 weeks’ estation: impact of revised practice guidelines Arij Faksh, DO; Joseph R. Wax, MD; F. Lee Lucas, PhD; Angelina Cartin; Michael G. Pinette, MD OBJECTIVE: The purpose of this study was to determine the perinatal impact of the 2007 American College of Obstetricians and Gynecolo- gists Practice Bulletin on preterm premature membrane rupture. STUDY DESIGN: Perinatal outcomes were compared in women who had experienced preterm membrane rupture in the 3 years before
  • 5. the 2007 Practice Bulletin to similar women who experienced preterm pre- mature rupture of membranes in the 3 years after the issue and imple- mentation of the guideline. RESULTS: After adjustment for gestational age at membrane rupture and steroids, composite severe morbidity (death, respiratory distress Obstet Gynecol 2011;205:340.e1-5. p remained uncertain, p doi: 10.1016/j.ajog.2011.05.036 340.e1 American Journal of Obstetrics & Gynecology OCTOBER 2011 syndrome, assisted ventilation for �6 hours, sepsis, pneumonia, grade 3 or 4 intraventricular hemorrhage, or necrotizing enterocolitis) was similar by group. Infants in the “after” group experienced less pneumo- nia and sepsis, similar respiratory morbidity, but more labor inductions and postpartum hemorrhage. CONCLUSION: The new guideline significantly decreases severe neo- natal infections but is associated with more frequent labor
  • 6. induction and postpartum hemorrhage. Key words: neonatal morbidity, prematurity, preterm premature rupture of membranes Cite this article as: Faksh A, Wax JR, Lucas FL, et al. Preterm premature rupture of membranes �32 weeks’ gestation: impact of revised practice guidelines. Am J m c p o t Preterm premature rupture of mem-branes (PPROM) affects 1- 2% of pregnancies but is associated with up to 30-40% of preterm births.1 In the ab- sence of labor or complications that war- rant delivery, expectant care is often practiced until a gestational age is reached beyond which further observa- tion does not significantly reduce pre- maturity complications but potentially exposes the fetus to infection and in- flammation with associated long-term From the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology (Drs Faksh, Wax, and Pinette and Ms Cartin), and the Maine Center for Outcome Research and Evaluation (Dr Lucas), Maine Medical Center, Portland, ME. Received Feb. 9, 2011; revised April 5, 2011;
  • 7. accepted May 18, 2011. J.R.W. reports having served periodically as a consultant to the Gerson Lehrman Group over the past 3 years. The other 4 authors report no conflicts of interest. Presented orally at the District I Meeting, American College of Obstetricians and Gynecologists, Bar Harbor, ME, Oct. 8-10, 2010. Reprints not available from the authors. 0002-9378/$36.00 © 2011 Mosby, Inc. All rights reserved. negative consequences. Contemporary PPROM management incorporates glu- cocorticoids, broad-spectrum antibiot- ics, and fetal lung maturity assessment. Perinatal outcomes that are associated with this care suggest that expectancy may be abandoned at earlier gestational ages than previously considered.2-5 In April 2007, the American College of Obstetricians and Gynecologists (ACOG) published a revised Practice Bulletin that supported more active PPROM manage- ment at earlier gestational ages.6 However, 2 of 3 recommendations regarding deliv- ery timing were based on limited and in- consistent scientific evidence (level B) and included delivery at 32-33 weeks’ gestation with documented fetal lung maturity or when PPROM occurred at �34 weeks’
  • 8. gestation. An additional recommendation to consider a single course of corticoste- roids at 32-33 weeks’ gestation, particu- larly if pulmonary immaturity was docu- mented, was based primarily on consensus and expert opinion (level C). Moreover, many supporting studies were conducted among predominantly African American women,3-5 whose offspring demonstrate accelerated lung maturation compared with white women.7,8 Thus, the antici- ated benefits of the new practice guideline articularly in a pri- arily white population. We therefore onducted a retrospective study that com- ared short-term maternal and neonatal utcomes before vs after the implementa- ion of the 2007 Practice Bulletin. ME T H O D S This retrospective, institutional review board– exempt study included all women with a single living nonanomalous fetus who had experienced PPROM at 32 0/7 to 35 6/7 weeks’ gestation from January 1, 2004, to April 1, 2010, and who received care in a single tertiary teaching hospital. A best obstetric estimate of gestational age was determined with the use of menstrual data and first- or second-trimester ultra- sonography. Rupture of membranes was diagnosed by sterile speculum examina- tion that confirmed the pooling of amni-
  • 9. otic fluid in the vagina, positive nitrazine paper test, and positive ferning test. Those women with PPROM in the 3 years before guideline implementation on April 1, 2007, were compared with those with PPROM in the subsequent 3 years with re- gard to maternal and newborn character- istics and outcomes. The primary outcome was composite severe neonatal morbidity (any one of the following occurrences: death, respiratory distress syndrome [RDS], assisted ventilation for �6 hours, sepsis, t � v o r a c a s i l e t n a o a
  • 10. p l f e 011. www.AJOG.org Obstetrics Research pneumonia, grade 3 or 4 intraventricular hemorrhage [IVH], or necrotizing entero- colitis). Secondary outcomes included neonatal intensive care unit (NICU) ad- mission, NICU length of stay, respiratory morbidity (RDS or assisted ventilation for �6 hours), and infectious morbidity (cul- ture-proven sepsis or pneumonia). Women in the “before” group re- ceived inpatient care that consisted of a single course of glucocorticoid therapy at 32 0/7 to 33 6/7 weeks’ gestation, a 2-day course of intravenous ampicillin followed by 5 days of oral amoxicillin, and a single 1-g oral dose of azithromy- cin. Tocolytics were used at physician discretion for up to 48 hours to permit steroid administration. Fetal surveil- lance included daily biophysical profiles and nonstress tests every 4-8 hours. De- livery ensued after spontaneous labor, documentation of fetal lung maturity by the presence of phosphatidylglycerol in amniotic fluid that was obtained from the vaginal pool or by amniocentesis at 32-36 weeks’ gestation, when 35-36 weeks’ gestation was achieved or sooner
  • 11. for nonreassuring fetal status or clinical chorioamnionitis. Women in the “after” group received identical care, which varied only with re- gard to delivery timing. Again, delivery followed spontaneous labor, nonreas- suring fetal status, or clinical chorioam- nionitis. Alternatively, women in the af- TABLE 1 Maternal characteristics Demographic Before Age, ya 28.4 � ............................................................................................... .................... Body mass index, kg/m2a 31.2 � ............................................................................................... .................... White, n (%) 103 (96 ............................................................................................... .................... Parity, n ............................................................................................... ........... 0 69 ............................................................................................... ........... 1 19
  • 12. ............................................................................................... ........... �2 19 ............................................................................................... .................... Tobacco use, n (%) 34 (31 ............................................................................................... .................... Previous loop electric excision procedure/cone biopsy, n (%) 8 (7. ............................................................................................... .................... a Data are given as mean � SD. Faksh. Revised PPROM guideline. Am J Obstet Gynecol 2 ter group were also delivered at 32 0/7 to t 33 6/7 weeks’ gestation if amniotic fluid was obtained from the vaginal pool or by amniocentesis and demonstrated that phosphatidylglycerol was present. If the fluid could not be collected or lung ma- turity was not demonstrated, delivery was initiated at 34 0/7 weeks’ gestation. Finally, delivery was expedited on ad- mission for PPROM after 34 0/7 weeks’ gestation. As of September 2008, a change in NICU admission policy oc- curred, whereby all infants who were born after PPROM �36 0/7 weeks’ ges- tation were admitted to the NICU or
  • 13. intermediate care nursery where they re- mained until hospital discharge. Pre- viously, 35-week infants were triaged in the delivery room based on respiratory status. Infants who were born at �35 0/7 in both time periods routinely were ad- mitted to the NICU; those infants who were born at �36 weeks’ gestation in both time periods were triaged in the de- livery room based on respiratory status. Maternal characteristics, management, interventions, and outcomes were com- pared by study group. Morbidity included chorioamnionitis (diagnosed by �2 of he following occurrences: maternal fever 38.0°C, uterine tenderness, malodorous aginal discharge, maternal leukocytosis, r fetal tachycardia), postpartum hemor- hage (estimated blood loss �500 mL after vaginal delivery and �1000 mL after a esarean delivery), postpartum endome- 107) After (n � 64) P value .8 26.4 � 6.1 .04 ............................................................................................... ................... .9 31.5 � 7.9 .81 ............................................................................................... ................... 62 (96.9) .83
  • 14. ............................................................................................... ................... .66 ............................................................................................... ................... 39 ............................................................................... ................ ................... 15 ............................................................................................... ................... 10 ............................................................................................... ................... 22 (34.4) .73 ............................................................................................... ................... 5 (7.8) .94 .............................................................................................. . ................... ritis (maternal temperature of �38.0°C OCTOBER 2011 Americ fter the first 24 postpartum hours with as- ociated uterine tenderness), and wound nfection (periincisional erythema, puru- ent drainage, or induration in the postop- rative period that required antibiotic herapy).
  • 15. Data were abstracted from the mater- al prenatal record, and the maternal nd newborn inpatient records. Dichot- mous and continuous variables were nalyzed with the chi-square and un- aired t-test, respectively. Logistic and inear regression analyses were adjusted or covariates. Significance was consid- red for a probability value of � .05. RE S U L T S One hundred seventy-one eligible subjects were included: 107 women before and 64 women after guideline implementation. Maternal demographics were similar by study group (Table 1). Women who were cared for under the new guideline were less likely to be treated expectantly, despite having experienced PPROM at an earlier average gestational age. They also more of- ten received steroids to accelerate fetal lung maturity. After adjustment for differences in gestational age at PPROM, this group more often had labor induced and deliv- ered on average 1 week earlier than women with PPROM before the new guideline (Table 2). Despite the increased induction rate, primary and total cesarean delivery rates were similar by group. Maternal mor- bidity, including clinical and histologic chorioamnionitis, occurred with similar frequency by study group, except for the later cohort that experienced more post- partum hemorrhages. There were no
  • 16. blood transfusions, however, in any sub- jects (Table 3). Newborn infant outcomes were ad- justed for differences in gestational age at PPROM and steroid administration. There was no significant difference in the frequency of composite morbidity by time period (Table 4). No infant had a severe IVH or necrotizing enterocolitis. There were 2 cases of suspected intra- uterine growth restriction (estimated fe- tal weight or abdominal circumference �10% for gestational age) in the before group and 1 case in the after group. The (n � 5 ......... 6 ......... .3) ......... ......... ......... ......... ......... .8) .........
  • 17. 5) ......... only death occurred from disseminated an Journal of Obstetrics & Gynecology 340.e2 . o s c p p b w 2 a i s A m g l t p t a p o i
  • 18. e b w 3 t s p v f p i 011. Research Obstetrics www.AJOG.org herpes infection in a newborn infant of a mother with no history or physical find- ings of infection. Neonates who were born after guideline implementation were more likely to be admitted to the NICU and experience longer NICU stays. These offspring had significantly fewer diagnoses of severe infections, yet no significantly increased rate of respira- tory complications (Table 4). Infants in the before group weighed more than those in the after group (2387 � 373 g vs 2233 � 365 g; P � .009). There was no difference in the frequency of 5-minute Apgar scores of �7 (1.9% vs 4.7%; P � 3).Umbilical arterial cord blood pH was btained in all cases; no infant demon- trated a pH �7.00. CO M M E N T Our study demonstrates that the imple-
  • 19. mentation of and adherence to recent PPROM management guidelines signif- icantly reduces the composite outcome of neonatal sepsis and pneumonia with- out increasing newborn infant compos- ite morbidity among women who expe- rience PPROM at �32 weeks’ gestation. However, this benefit is associated with significantly more frequent maternal la- bor induction, postpartum hemorrhage, increased NICU use, and a statistically nonsignificant increase in respiratory morbidity. Importantly, the increased induction rate did not raise the primary or overall cesarean delivery rates, and no maternal transfusions were required. The increased NICU use that was ob- served under the new guideline likely re- flects, at least in part, the described change in neonatal admission policy. These results provide important data regarding the 2007 ACOG PPROM prac- tice bulletin recommendations, particu- larly regarding delivery timing. Several supporting studies that were referenced by the bulletin included mostly urban African American women, who com- prised 55-79.6% of the subjects.3-5 After ontrolling for population differences, reterm infants born to black women ex- erience significantly less hyaline mem- rane disease than those born to white omen on a week-by-week basis from 6-37 weeks.7 Therefore, the generaliz- B
  • 20. 340.e3 American Journal of Obstetrics & Gynecolo bility of the earlier findings and result- ng practice recommendations to dis- imilar populations remained uncertain. lthough the difference in respiratory orbidity rates between our study roups was not statistically significant, a arger study population could result in his difference becoming significant. A ost hoc sample size calculation showed hat 257 patients in each group would chieve statistical significance with 80% ower at the .05 level. A recent evaluation of ACOG Practice TABLE 2 Management of preterm premature Characteristics Be Gestational age at PPROM, wka 3 ............................................................................................... .................... Gestational age at delivery, wka 3 ............................................................................................... .................... Expectant care, n (%) 7 ............................................................................................... .................... Latency, da,c
  • 21. ............................................................................................... .................... Steroids, n (%) 6 ............................................................................................... .................... Antibiotics, n (%) 10 ............................................................................................... .................... Tocolytic, n (%) 2 ............................................................................................... .................... Amniotic fluid tested for maturity, n (%) 7 ............................................................................................... .................... Amniotic fluid test mature, n (%) 3 ............................................................................................... .................... Labor induction, n (%) 2 ............................................................................................... ........... Indications ............................................................................................... .. 34 wk ............................................................................................... .. Lung maturity 2
  • 22. ............................................................................................... .. Clinical chorioamnionitis ............................................................................................... .. Nonreassuring fetal status ............................................................................................... .................... Cesarean delivery, n (%) ............................................................................................... ........... Primary 2 ............................................................................................... ........... Total 3 ............................................................................................... ........... Indications ............................................................................................... .. Nonreassuring fetal status 1 ............................................................................................... .. Malpresentation ............................................................................................... .. Cephalopelvic disproportion
  • 23. ............................................................................................... .. Chorioamnionitis ............................................................................................... .. Repeat ............................................................................................... .. Elective ............................................................................................... .. Abruption ............................................................................................... .................... PPROM, preterm premature rupture of membranes. a Data are given as mean � SD; b Adjusted for gestational a expectantly; d Adjusted for gestational age at PPROM and st Faksh. Revised PPROM guideline. Am J Obstet Gynecol 2 ulletins observed that only 23% of rec- gy OCTOBER 2011 mmendations regarding obstetrics top- cs were based on good and consistent vidence (level A).9 The 2007 PPROM ulletin offered 11 recommendations, of hich 5 (45%) were level A. Notably, 2 of recommendations regarding delivery iming were based on limited and incon-
  • 24. istent scientific data. Moreover, although ractice guidelines should reduce practice ariation and improve health outcomes, ew studies evaluate these intended and otentially unintended consequences of mplementation.10 Therefore, it is impor- pture of membranes e (n � 107) After (n � 64) P value � 1.0 33.2 � 0.9 .0001 ............................................................................................... ................... � 0.9 33.6 � 0.8 .0001b ............................................................................................... ................... 1.0) 34 (53.1) .02 ............................................................................................... ................... � 4.0 4.5 � 3.2 .57 ............................................................................................... ................... 4.5) 54 (84.4) .004 ............................................................................................... ................... 00) 63 (98.4) NS ............................................................................................... ...................
  • 25. 3.4) 11 (17.2) .34 ............................................................................................... ................... 5.4) 22 (34.3) .001d ............................................................................................... ................... 4.3) 6 (27.7) .4 ............................................................................................... ................... 7.1) 35 (54.7) � .0001d ............................................................................................... ................... ............................................................................................... ................... 26 ............................................................................................... ................... 4 ............................................................................................... ................... 3 ............................................................................................... ................... 2 ............................................................................................... ................... ...............................................................................................
  • 26. ................... 3.4) 15 (23.4) .53 ............................................................................................... ................... 2.7) 18 (28.1) ............................................................................................... ................... ............................................................................................... ................... 8 ............................................................................................... ................... 4 ............................................................................................... ................... 2 ............................................................................................... ................... 1 ............................................................................................... ................... 1 ......................................................................................... ...... ................... 2 ............................................................................................... ...................
  • 27. 0 ............................................................................................... ................... t PPROM; c Includes only those patients who were managed s. ru for 3.9 ......... 4.4 ......... 6 (7 ......... 4.9 ......... 9 (6 ......... 7 (1 ......... 5 (2 ......... 0 (6 ......... 1 (4
  • 29. ......... 3 ......... 6 ......... 1 ......... 1 ......... ge a eroid tant to examine a guideline’s impact on t i l c o a r t t a a e c d q
  • 30. a T g f I n p b c t i a t T p w 011. www.AJOG.org Obstetrics Research populations that are different from those that generated the recommendations, par- ticularly when the recommendations were based on inconsistent supporting evi- dence. Our data confirm the anticipated benefits of less frequent neonatal infec- tious morbidity. However, the results raise questions about the neonatal respiratory consequences of current delivery recom- mendations after PPROM in a 97% white population. The increased frequencies of labor induction and postpartum hemor- rhage also deserve further attention. Seven randomized trials that have cov-
  • 31. ered a total of 690 subjects have examined expectant vs planned early delivery in TABLE 3 Maternal morbidity Outcome Be Chorioamnionitis, n (%) ............................................................................................... ........... Clinical 10 ............................................................................................... ........... Histologic 47 ............................................................................................... .................... Postpartum hemorrhage, n (%) 5 ............................................................................................. .. .................... Transfusion, n 0 ............................................................................................... .................... Endometritis or wound infection, n (%) 4 ............................................................................................... .................... Faksh. Revised PPROM guideline. Am J Obstet Gynecol 2 TABLE 4 Neonatal outcomesa
  • 32. Outcome Primary, n (%) ......................................................................................... ...... ........... Death ............................................................................................... ........... Respiratory distress syndrome ............................................................................................. .. ........... Assisted ventilation ............................................................................................... ........... Sepsis ............................................................................................... ........... Pneumonia ............................................................................................... ........... Grade 3/4 intraventricular hemorrhage ............................................................................................... ........... Necrotizing enterocolitis ............................................................................................... ........... Composite
  • 33. ............................................................................................... .................... Secondary ............................................................................................... ........... Neonatal intensive care unit ............................................................................................. .. .. Admission, n (%) ............................................................................................... .. Stay, db ............................................................................................... ........... Respiratory morbidity, n (%) ............................................................................................... ........... Infectious morbidity, n (%) ............................................................................................... .................... a Adjusted for gestational age at preterm premature rupture o Faksh. Revised PPROM guideline. Am J Obstet Gynecol 2011. pregnancies that were complicated by PPROM.3-5,11-14 These studies are difficult o compare with each other and with our nvestigation because of many methodo- ogic differences, such as the time period overed by the study, the gestational ages f included subjects, the administration of ntibiotics and steroids, tocolytic use, the
  • 34. ole of amniotic fluid fetal lung maturity esting in pregnancy management, the iming of planned delivery after PPROM, nd the outcome measures. A recent meta- nalysis of these trials found that planned arly delivery was associated with in- reased rates of labor induction, cesarean elivery, and endometritis but less fre- e (n � 107) After (n � 64) P value ............................................................................................... ................... 3) 5 (7.8) .73 ............................................................................... ................ ................... .9) 20 (31.3) .10 ............................................................................................... ................... 7) 12 (18.8) .003 ............................................................................................... ................... 0 — ............................................................................................... ................... 7) 1 (1.6%) .39 ............................................................................................... ................... ore (n � 107) After (n � 64) P value
  • 35. ............................................................................................... ................... (0.9) 0 .81 ............................................................................................... ................... (11.2) 14 (21.9) .23 ............................................................................................... ................... (17.8) 21 (32.8) .06 ............................................................................................... ................... (4.7) 1 (1.6) .08 ............................................................................................... ................... (7.5) 1 (1.6) .14 ............................................................................................... ................... 0 — ............................................................................................... ................... 0 — ............................................................................................... ................... (23.4) 21 (32.8) .42 ............................................................................................... ................... ...............................................................................................
  • 36. ................... ............................................................................................... ................... (72.9) 62 (96.9) .03 ............................................................................................... ................... 2 � 3.3 5.0 � 3.2 .05 ............................................................................................... ................... (18.9) 21 (32.8) .09 ............................................................................................... ................... (11.2) 2 (3.2) .04 ............................................................................................... ................... mbranes and steroids; b Data are given as mean � SD. OCTOBER 2011 Americ uently with suspected neonatal infection nd newborn infant antibiotic treatment. here were no differences by group re- arding perinatal, neonatal, or intrauterine etal deaths or morbidities of IVH or RDS. nterestingly, frequencies of chorioamnio- itis, positive neonatal blood cultures, and neumonia were not significantly different y management approach. The authors oncluded that insufficient evidence exists o guide clinical decision-making regard- ng immediate delivery vs expectant man- gement of PPROM, citing inadequate sta-
  • 37. istical power.1 A prospective cohort study compared neonatal outcomes after expectant vs elec- tive delivery of PPROM between 24 0/7 to 33 6/7 weeks’ gestation. Similar to our management, antepartum care included antibiotics and steroids. As in the current report, the frequency of RDS was statisti- cally similar in both groups, although sep- sis was less frequent with elective delivery. Contrasting our findings, a significant re- duction in the rate of grade 3 or 4 IVH led to a decrease in severe composite morbid- ity among electively delivered infants, probably related to the earlier gestational ages of included PPROM subjects. This group also had a higher cesarean delivery rate, which reflected the increased inci- dence of nonvertex presenting fetuses, again likely a consequence of early gesta- tional ages at membrane rupture.2 A retrospective investigation of pa- tients who experience PPROM at �24 weeks’ gestation and who delivered at �37 weeks’ gestation from 1998-2000 examined maternal and neonatal com- plications to determine an ideal gesta- tional age for delivery. Steroids and broad-spectrum antibiotics were admin- istered routinely. If phosphatidylglycerol was present in vaginal pool fluid at �32 weeks’ gestation, delivery was expedited. When compared with pregnancies with PPROM delivery at 36 0/7 to 36 6/7 weeks’
  • 38. gestation, major and minor composite neonatal morbidity were increased among those infants who were delivered at �33 and �34 weeks’ gestation, respectively. he authors questioned the benefit of ex- ectant management of PPROM at �34 eeks’ gestation.15 The limited short-term neonatal bene- for ......... (9. ......... (43 ......... (4. ......... ......... (3. ......... Bef ......... 1 ......... 12 .........
  • 40. fits of expectant management of PPROM an Journal of Obstetrics & Gynecology 340.e4 1 s a o a n a Research Obstetrics www.AJOG.org that were noted in the current and earlier studies likely reflect several factors. Con- temporary maternal and neonatal care that features antepartum steroids, broad-spec- trum antibiotics, selective tocolytic use, and improved NICU care are probable contributors to the observed outcomes. Additionally, the relatively short latency period that is anticipated with expectant care of PPROM at �34 weeks’ gestation may be insufficient to favorably impact short-term neonatal outcomes. One re- port noted latencies at �48 hours in only 0.4% of such cases.16 Another article de- cribed a mean latency of 2.4 � 3.1 days mong these women.15 The similarly short mean latency intervals that we observed, coupled with later mean gestational ages of PPROM that were studied, support this
  • 41. explanation. Chorioamnionitis and the accompa- nying inflammatory response have been implicated in adverse long-term neuro- logic sequelae among exposed offspring.17 An important rationale for the active man- agement of PPROM is to minimize the risks that are associated with such expo- sures. However, contrasting most previous studies, we found no differences in the rates of clinical or histologic chorioamnio- nitis between expectantly and actively managed PPROM.3,4,5,11 We suspect that ur findings reflect the shorter latencies nd less frequent inflammation that are oted with PPROM at later gestational ges, such as those included in our study.18 This observation is strengthened by the availability of placental pathologic findings for all subjects in both time periods of our study. Our report offers several strengths be- yond those already mentioned. Data were drawn from a single institution with 1 ma- ternal fetal medicine group and 1 neona- tology group providing consistent patient care. One institutional guideline for ante- partum care was in effect for each time pe- riod. No obstetrical practice changes other than delivery timing resulted from guide- line implementation. Neonatal practice
  • 42. changed only with regard to the described admission policy. Therefore, we believe that the observed results, with the possible exception of NICU use, likely stem from the revised delivery policy. We recognize several limitations, including the retro- 340.e5 American Journal of Obstetrics & Gynecolo spective study design and population differences among subjects in the 2 time periods that were examined. However, re- gression analyses adjusted for differences in confounders between the 2 groups. Be- cause the patients were drawn from a ter- tiary referral center, the data may not re- flect population-based rates of the various outcome measures. Although the homo- geneity of our population was a strength in addressing our research question, it may limit generalizability of our results to dis- similar patients. In summary, the implementation of the 2007 ACOG PPROM Practice Bulletin guidelines in our population significantly reduced severe neonatal infectious mor- bidity without significantly exacerbating composite morbidity. However, these benefits must be balanced against in- creased induction and hemorrhage rates, coupled with concerns for increased neo- natal respiratory morbidity. We also ob- served increased intensive care use, even after adjusting for earlier gestational age at
  • 43. PPROM and increased steroid use, which may reflect changes in neonatal admission policy. Additional research should also evaluate the cost-effectiveness of imple- mentation of the guideline’s recommen- dations and the subsequent impact on long-term childhood pulmonary, neuro- logic, and developmental sequelae. A ran- domized trial of expectant vs active man- agement of PPROM at �32 weeks’ gestation would shed important light on these uncertainties. f REFERENCES 1. Buchanan SL, Crowther CA, Levett KM, Middleton P, Morris J. Planned early birth ver- sus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks’ gestation for improving pregnancy outcome. Cochrane Database Syst Rev 2010; 3:CD004735. 2. Pasquier JC, Picaud JC, Rabilloud M, et al. Neonatal outcomes after elective delivery man- agement of preterm premature rupture of the membranes before 34 weeks’ gestation (DOMINOS study). Eur J Obstet Gynecol Re- prod Biol 2009;143:18-23. 3. Mercer BM, Crocker LB, Boe NM, Sibai BM. Induction versus expectant management in pre- mature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial. Am J Obstet Gynecol 1993;169:775-82. 4. Naef RW, Allbert JR, Ross EL, Weber BM, Martin RW, Morrison JC. Premature rupture of
  • 44. gy OCTOBER 2011 membranes at 34 to 37 weeks’ gestation: aggressive versus conservative management. Am J Obstet Gynecol 1998;178:126-30. 5. Cox SM, Leveno KJ. Intentional delivery ver- sus expectant management with preterm rup- tured membranes at 30-34 weeks’ gestation. Obstet Gynecol 1995;86:875-9. 6. American College of Obstetricians and Gyne- cologists. Premature rupture of membranes: ACOG practice bulletin no. 80. Obstet Gynecol 2007;109:1007-19. 7. Hulsey TC, Alexander GR, Robillard PY, Anni- bale DJ, Keenan A. Hyaline membrane disease: the role of ethnicity and maternal risk characteris- tics. Am J Obstet Gynecol 1993;168:572-6. 8. Richardson DK, Torday JS. Racial differences in predictive value of the lecithin/sphingomyelin ratio. Am J Obstet Gynecol 1994;170:1273-8. 9. Chauhan SP, Berghella V, Sanderson M, Magann EF, Morrison JC. American College of Obstetricians and Gynecologists practice bulle- tins: an overview. Am J Obstet Gynecol 2006; 194:1564-75. 10. Shackelton RJ, Marceau CD, Link CL, McKinlay JB. The intended and unintended consequences of clinical guidelines. J Eval Clin Pract 2009;15:1035-42. 11. Spinnato JA, Shaver DC, Bray EM, Lipshitz J. Preterm premature rupture of the membranes with fetal pulmonary maturity present: a prospec- tive study. Obstet Gynecol 1987;69:196-201. 12. Garite TJ, Freeman RK, Linzey EM, Braley PA, Dorchester WL. Prospective randomized study of corticosteroids in the management of
  • 45. premature rupture of the membranes and the premature gestation. Am J Obstet Gynecol 1981;141:508-15. 13. Iams JD, Talbert ML, Barrows H, Sacks L. Management of preterm prematurely ruptured membranes: a prospective randomized com- parison of observation versus use of steroids and timed delivery. Am J Obstet Gynecol 1985;151:32-8. 14. Nelson LH, Meis PJ, Hatjis C, Ernest JM, Dillard R, Schey HM. Premature rupture of membranes: a prospective, randomized evalu- ation of steroids, latent phase, and expectant management. Obstet Gynecol 1985;66:55-8. 15. Lieman JM, Brumfield CG, Carlo W, Ram- sey PS. Preterm premature rupture of mem- branes: is there an optimal gestational age for delivery? Obstet Gynecol 2005;105:12-7. 16. Neerhof MG, Cravello C, Haney EI, Silver RK. Timing of labor induction after premature rupture of membranes between 32 and 36 weeks’ ges- tation. Obstet Gynecol 1999:180:349-52. 17. Shatrov JG, Birch SC, Lam LT, Quinlivin JA, McIntyre S, Mendz GL. Chorioamnionitis and cerebral palsy: a meta-analysis. Obstet Gynecol 2010;116:387-92. 18. Ramsey PS, Lieman JM, Brumfield CG, Carlo W. Chorioamnionitis increases neonatal morbidity in pregnancies complicated by pre- term premature rupture of membranes. Am J Obstet Gynecol 2005;192:1162-6. Preterm premature rupture of membranes ≥32 weeks` gestation: impact of revised practice g ...MethodsResultsCommentReferences
  • 46. 918 VOL. 122, NO. 4, OCTOBER 2013 OBSTETRICS & GYNECOLOGY Background The definition of PROM is rupture of membranes before the onset of labor. Membrane rupture before labor and before 37 weeks of gestation is referred to as preterm PROM. Management is influenced by gestational age and the presence of complicating factors, such as clini- cal infection, abruptio placentae, labor, or nonreasurring fetal status. An accurate assessment of gestational age and knowledge of the maternal, fetal, and neonatal risks are essential to appropriate evaluation, counseling, and care of patients with PROM. Etiology of Premature Rupture of Membranes Membrane rupture may occur for a variety of reasons. Although membrane rupture at term can result from a normal physiologic weakening of the membranes combined with shearing forces created by uterine contractions, preterm PROM can result from a wide array of pathologic mechanisms that act individually or in concert (4, 5). Intraamniotic infection has been shown to be commonly associated with preterm PROM, especially at earlier gestational ages (6). A history of preterm PROM is a major risk factor for preterm PROM or preterm labor in a subsequent pregnancy (7, 8). Additional risk factors associated with preterm PROM are similar to those associated with spontaneous preterm birth and include short cervical length, second-trimester
  • 47. and third-trimester bleeding, low body mass index, low socioeconomic status, cigarette smoking, and illicit drug use (9–12). Although each of these risk factors is associ- ated with preterm PROM, it often occurs in the absence of recognized risk factors or an obvious cause. Term Premature Rupture of Membranes At term, PROM complicates approximately 8% of preg- nancies and generally is followed by the prompt onset of spontaneous labor and delivery. In a large randomized trial, one half of women with PROM who were managed expectantly gave birth within 5 hours and 95% gave birth within 28 hours of membrane rupture (13). The most Premature Rupture of Membranes Preterm delivery occurs in approximately 12% of all births in the United States and is a major factor that contributes to perinatal morbidity and mortality (1, 2). Preterm premature rupture of membranes (PROM) complicates approxi- mately 3% of all pregnancies in the United States (3). The optimal approach to clinical assessment and treatment of women with term and preterm PROM remains controversial. Management hinges on knowledge of gestational age and evaluation of the relative risks of delivery versus the risks of expectant management (eg, infection, abruptio placentae, and umbilical cord accident). The purpose of this document is to review the current understanding of this condition and to provide management guidelines that have been validated by appropriately conducted outcome-based research when available. Additional guidelines on the basis of consensus and expert opinion also are presented. Committee on Practice Bulletins—Obstetrics. This Practice Bulletin was developed by the Committee on Practice Bulletins—Obstetrics with the assis- tance of Robert Ehsanipoor, MD. The information is designed to
  • 48. aid practitioners in making decisions about appropriate obstetric and gynecologic care. These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice. NUMBER 139, OCTOBER 2013 (Replaces Practice Bulletin Number 80, April 2007 and Committee Opinion Number 475, February 2011) P RACTICE BULLET IN CLINICAL MANAGEMENT GUIDELINES FOR OBSTETRICIAN–GYNECOLOGISTS The American College of Obstetricians and Gynecologists WOMEN’S HEALTH CARE PHYSICIANS VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin Premature Rupture of Membranes 919 significant maternal consequence of term PROM is intrauterine infection, the risk of which increases with the duration of membrane rupture. Preterm Premature Rupture of Membranes Regardless of obstetric management or clinical presen- tation, birth within 1 week of membrane rupture occurs in at least one half of patients with preterm PROM (5). Latency after membrane rupture is inversely correlated with the gestational age at membrane rupture (14).
  • 49. Cessation of amniotic fluid leakage with restoration of normal amniotic fluid volume may occur in the setting of spontaneous preterm PROM and is associated with favorable outcomes (15). Among women with preterm PROM, clinically evident intraamniotic infection occurs in approxi- mately 15–25% (16), and postpartum infection occurs in approximately 15–20%; the incidence of infection is higher at earlier gestational ages (6, 17). Abruptio pla- centae complicates 2–5% of pregnancies with preterm PROM (18, 19). The most significant risks to the fetus after preterm PROM are complications of prematurity. Respiratory distress has been reported to be the most common com- plication of preterm birth (20). Sepsis, intraventricular hemorrhage, and necrotizing enterocolitis also are asso- ciated with prematurity, but these are less common near to term. Preterm PROM with intrauterine inflammation has been associated with an increased risk of neurode- velopmental impairment (21, 22), and early gestational age at membrane rupture also has been associated with an increased risk of neonatal white matter damage (23). However, there are no data that suggest that immediate delivery after presentation with PROM will avert these risks. Infection and umbilical cord accident contribute to the 1–2% risk of antenatal fetal demise after preterm PROM (24). Previable Premature Rupture of Membranes Rupture of the membranes before viability occurs in less than 1% of pregnancies. The probability of neonatal death and morbidity associated with PROM decrease with longer latency and advancing gestational age (25). In a
  • 50. review of preterm PROM between 14 weeks and 24 weeks of gestation, perinatal deaths were more or less equally divided between stillbirths and neonatal deaths. Survival rates were much improved with expectant management following membrane rupture after 22 weeks of gestation compared with membrane rupture before 22 weeks of gestation (57.7% versus 14.4%, respectively) (26). Most studies of second-trimester and previable PROM are retrospective and include only expectantly managed cases. Thus, they likely overestimate survival rates because of selection bias. Survival data may vary by institution. Significant maternal complications that occur after previable PROM include intraamniotic infection, endo- metritis, abruptio placentae, and retained placenta (26). Although it occurs infrequently, life-threatening mater- nal infection may complicate expectant management of previable PROM. Maternal sepsis is reported in approxi- mately 1% of cases (26), and isolated maternal deaths due to infection have been reported in this setting. Latency periods appear to be prolonged with second-trimester preterm PROM compared with later gestational ages. However, 40–50% of patients with previable PROM will give birth within the first week and approximately 70–80% will give birth 2–5 weeks after membrane rupture (26–28). The rate of pulmonary hypoplasia after PROM before 24 weeks of gestation varies widely among reports, but is likely in the range of 10–20%. Pulmonary hypoplasia is associated with a high risk of mortality (26), but is rarely lethal with membrane rupture sub- sequent to 23–24 weeks of gestation (29), presumably
  • 51. because alveolar growth adequate to support postnatal development already has occurred. Early gestational age at membrane rupture, and low residual amniotic fluid volume are the primary determinants of the incidence of pulmonary hypoplasia (30, 31). Prolonged oligohydramnios also can result in fetal deformations, including Potter-like facies (eg, low-set ears and epicanthal folds) and limb contractures or other positioning abnormalities. The reported frequency of skeletal deformations varies widely (1.5–38%) but many of these resolve with postnatal growth and physical therapy (26, 32). Clinical Considerations and Recommendations How is premature rupture of membranes diagnosed? Most cases of PROM can be diagnosed on the basis of the patient’s history and physical examination. Exam- ination should be performed in a manner that minimizes the risk of introducing infection. Because digital cervical examinations increase the risk of infection and add little information to that available with speculum examina- tion, digital examinations generally should be avoided unless the patient appears to be in active labor or delivery 920 Practice Bulletin Premature Rupture of Membranes OBSTETRICS & GYNECOLOGY seems imminent (33, 34). Sterile speculum examination provides an opportunity to inspect for cervicitis and
  • 52. umbilical cord prolapse or fetal prolapse, assess cervi- cal dilatation and effacement, and obtain cultures as appropriate. The diagnosis of membrane rupture typically is confirmed by the visualization of amniotic fluid pass- ing from the cervical canal and pooling in the vagina; a basic pH test of vaginal fluid; or arborization (ferning) of dried vaginal fluid, which is identified under micro- scopic evaluation. The normal pH of vaginal secretions is generally 4.5–6.0, whereas amniotic fluid usually has a pH of 7.1–7.3. False-positive test results may occur in the presence of blood or semen, alkaline antiseptics, or bacterial vaginosis. Alternatively, false-negative test results may occur with prolonged membrane rupture and minimal residual fluid. In equivocal cases, additional tests may aid in the diagnosis. Ultrasonographic examination of amniotic fluid volume may be a useful adjunct, but is not diag- nostic. Fetal fibronectin is a sensitive but nonspecific test for ruptured membranes; a negative test result is strongly suggestive of intact membranes, but a positive test result is not diagnostic of PROM (35). Several com- mercially available tests for amniotic proteins are cur- rently on the market, with high reported sensitivity for PROM (36, 37). However, false-positive test result rates of 19–30% have been reported in patients with clinically intact membranes and symptoms of labor (38, 39). These test kits should be considered ancillary to standard meth- ods of diagnosis. If the diagnosis remains unclear after a full evaluation, membrane rupture can be diagnosed unequivocally with ultrasonographically-guided transab- dominal instillation of indigo carmine dye, followed by the passage of blue-dyed fluid into the vagina, which is documented by a stained tampon or pad. It is important
  • 53. to note that the maternal urine also will turn blue and should not be confused with amniotic fluid. What does the initial management involve once PROM has been confirmed? In all patients with PROM, gestational age, fetal presen- tation, and fetal well-being should be determined. The examination should evaluate for evidence of intrauterine infection, abruptio placentae, and fetal compromise. If results are not already available and if an indication for treatment is not already present, culture for group B streptococci (GBS) should be obtained when expectant management is being considered. In patients with preterm PROM, an initial period of electronic fetal heart rate monitoring and uterine activity monitoring offers the opportunity to identify abnormal fetal heart rate tracings and to evaluate for contrac- tions (40). Management after confirmation of the diag- nosis of PROM is dependent primarily on gestational age and is discussed in more detail in the follow- ing paragraphs. Nonreassuring fetal status and clinical chorioamnionitis are indications for delivery. Vaginal bleeding should raise concern for abruptio placentae and also should prompt consideration of delivery, with the decision based on fetal status, the amount of bleeding, and gestational age. What is the optimal method of initial management for a patient with PROM at term? Gestational age and fetal position should be confirmed and fetal heart rate monitoring should be used to assess
  • 54. fetal status. Group B streptococcal prophylaxis should be given based on prior culture results or intrapartum risk factors if cultures have not been previously per- formed (41). A meta-analysis of 12 randomized controlled trials (6,814 women) found that induction of labor reduced the time to delivery and the rates of chorioamnionitis, endo- metritis, and admission to the neonatal intensive care unit without increasing the rates of cesarean delivery or operative vaginal delivery (42). The largest of these trials also found that women viewed induction of labor more positively than expectant management (13). Induction of labor with prostaglandins has been shown to be equally effective for labor induction compared with oxytocin but is associated with higher rates of chorioamnionitis (13). Infection is also a concern with mechanical methods of cervical ripening, such as the Foley balloon, but there are insufficient data on which to base a recommendation for mechanical methods of cervical ripening in the setting of PROM. A meta-analysis of two trials suggests that use of prophylactic antibiotics may reduce infectious mor- bidity, but prompt induction of labor was not standard care in either study. Thus, there is insufficient evidence to justify the routine use of prophylactic antibiotics with PROM at term in the absence of an indication for GBS prophylaxis (43–45). These meta-analysis data indicate that patients ben- efitted from induction of labor compared with expectant management and suggest that for women with PROM at 37 0/7 weeks of gestation or more, if spontaneous labor does not occur near the time of presentation in those who do not have contraindication to labor, labor should be induced, generally with oxytocin infusion. However, a course of expectant management may
  • 55. be acceptable for a patient who declines induction of labor as long as the clinical and fetal conditions are VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin Premature Rupture of Membranes 921 reassuring and she is adequately counseled regarding the risks of prolonged PROM. During induction of labor with oxytocin, a sufficient period of adequate contrac- tions (at least 12–18 hours) should be allowed for the latent phase of labor to progress before diagnosing failed induction and moving to cesarean delivery (46–48). When is delivery recommended for the preterm fetus in the presence of premature rupture of membranes? Nonreassuring fetal status, clinical chorioamnionitis, and significant abruptio placentae are clear indications for delivery. Otherwise, gestational age is a primary fac- tor when considering delivery versus expectant manage- ment (Box 1). However, the optimal gestational age for delivery is unclear and controversial. A meta-analysis of seven randomized controlled trials, including 690 women, concluded there was insufficient evidence to guide clini- cal practice regarding the risks and benefits of expectant management versus delivery in the setting of preterm PROM (49). The trials were insufficiently powered, had methodological weaknesses, and were variable in the gestational ages included. More recently, two randomized controlled trials
  • 56. evaluated delivery versus expectant management between 34 weeks and 37 weeks of gestation and included a total of 736 women (50, 51). Combining data from the two studies, induction of labor did not produce a statisti- cally significant reduction in the rate of neonatal sepsis (2.7% at 34 weeks versus 4.1% at 37 weeks of gestation, relative risk [RR], 0.66; 95% confidence interval [CI], 0.3–1.5). However, induction of labor did significantly reduce the risk of chorioamnionitis (1.6% at 34 weeks versus 5.3% at 37 weeks of gestation, RR, 0.31; 95% CI, 0.1–0.8), although there were no other significant differences between the two groups. These studies did not have sufficient power to show a statistically signifi- cant reduction in the rate of neonatal sepsis because the overall rate of sepsis was lower than anticipated. These findings are consistent with other smaller, similarly designed trials (52, 53) and those conducted in women at term (13, 42). Despite these data, the optimal gestational age for delivery remains controversial. Recently there has been a focus on the short-term (54) and long-term (55) risks associated with late preterm birth. However, the relevance of this to the management of women with ruptured membranes is unclear because neonates born from pregnancies complicated by preterm PROM have a higher rate of adverse outcomes compared with controls matched for gestational age (56). Furthermore, chorio- amnionitis, prolonged membrane rupture, and oligohy- dramnios are risk factors for adverse neonatal outcomes with preterm PROM (56, 57). At 34 0/7 weeks or greater of gestation, delivery is recommended for all women with ruptured membranes. If expectant management is continued beyond 34 0/7
  • 57. weeks of gestation, the balance between benefit and risk should be carefully considered and discussed with the patient, and expectant management should not extend beyond 37 0/7 weeks of gestation. Patients with PROM before 34 0/7 weeks of gestation should be managed Box 1. Chronologic Management of Premature Rupture of Membranes Early Term and Term (37 0/7 weeks of gestation or more) Late Preterm (34 0/7–36 6/7 weeks of gestation) Preterm (24 0/7–33 6/7 weeks of gestation)* † Less than 24 weeks of gestation‡ † ‡ 922 Practice Bulletin Premature Rupture of Membranes OBSTETRICS & GYNECOLOGY Should antenatal corticosteroids be administered to patients with preterm PROM? The use of antenatal corticosteroid administration after preterm PROM has been evaluated in a number of clinical trials and has been shown to reduce neonatal mortality, respiratory distress syndrome, intraventricu- lar hemorrhage, and necrotizing enterocolitis (64, 65).
  • 58. Current data suggest that antenatal corticosteroids are not associated with increased risks of maternal or neonatal infection regardless of gestational age. A single course of corticosteroids is recommended for pregnant women between 24 0/7 weeks and 34 0/7 weeks of gestation who are at risk of preterm delivery (66). A Cochrane meta-analysis reinforces the beneficial effect of this therapy regardless of membrane status and concludes that a single course of antenatal corticosteroids should be considered routine for all preterm deliveries (64). There are no data that support the use of corticosteroids before viability, and administration of corticosteroids in this setting is not currently recommended. Weekly administration of corticosteroids has been associated with a reduction in birth weight and head cir- cumference and is not recommended (67–69). Whether to administer a rescue course of corticosteroids with PROM is controversial, and there is insufficient evi- dence to make a recommendation for or against. Should magnesium sulfate for fetal neuro- protection be administered to patients with preterm PROM? Randomized controlled trials have demonstrated that maternal administration of magnesium sulfate used for fetal neuroprotection when birth is anticipated before 32 0/7 weeks of gestation reduces the risk of cerebral palsy in surviving infants (RR, 0.71; 95% CI, 0.55–0.91) (70). In the largest of these trials, 85% of the women enrolled had preterm PROM between 24 weeks and 32 weeks of gestation (71). The optimal treatment regimen for fetal neuroprotection remains unclear, and different regimens were used in different trials. Hospitals that elect to use magnesium sulfate for fetal neuroprotec-
  • 59. tion should develop uniform and specific guidelines for their departments regarding inclusion criteria, treat- ment regimens, concurrent tocolysis, and monitoring in accordance with one of the larger trials (71–73). Regardless of the treatment regimen used, women with preterm PROM before 32 0/7 weeks of gestation who are thought to be at risk of imminent delivery should be considered candidates for fetal neuroprotective treat- ment with magnesium sulfate. expectantly if no maternal or fetal contraindications exist (53). What general approaches are used in cases of preterm PROM managed expectantly? Expectant management of preterm PROM generally consists of hospital admission with periodic assess- ment for infection, abruptio placentae, umbilical cord compression, fetal well-being, and labor. There is no consensus on the optimal frequency of assessment, but an acceptable strategy would include periodic ultraso- nographic monitoring of fetal growth and periodic fetal heart rate monitoring. A temperature elevation may indi- cate intrauterine infection. Prompt diagnosis of chorio- amnionitis in preterm pregnancy requires a high index of suspicion because early signs and symptoms may be subtle. In the absence of fever, other clinical criteria have variable sensitivity and specificity for diagnosing infection. Serial monitoring of leukocyte counts and other markers of inflammation have not been proved to be useful and are nonspecific when there is no clinical evidence of infection, especially if antenatal corticoste- roids have been administered (58). Specific management considerations regarding tocolytics, corticosteroids, anti- biotics, magnesium sulfate, and timing of delivery are
  • 60. discussed in detail as follows. Should tocolytics be considered for patients with preterm PROM? The use of tocolysis in the setting of preterm PROM is controversial and practice patterns among specialists vary widely (59). There are insufficient data to support or refute the use of prophylactic tocolysis in the setting of preterm PROM. A meta-analysis of eight trials that included 408 women is of limited use because women were only treated in two of the trials (60, 61) with latency antibiotics and corticosteroids, both of which have become part of standard management (62). The use of tocolysis was associated with a longer latency period and a lower risk of delivery within 48 hours but also was associated with a high risk of chorioamnionitis in preg- nancies before 34 0/7 weeks of gestation. In summary, prophylactic tocolysis may be associated with a prolon- gation of pregnancy and an increased risk of chorioam- nionitis without significant maternal or neonatal benefit, although its use has not been evaluated adequately with latency antibiotics and corticosteroids. In the setting of ruptured membranes with active labor, therapeutic tocol- ysis has not been shown to prolong latency or improve neonatal outcomes. Therefore, therapeutic tocolysis is not recommended (63). VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin Premature Rupture of Membranes 923 Should antibiotics be administered to patients with preterm PROM?
  • 61. Administration of broad-spectrum antibiotics prolongs pregnancy, reduces maternal and neonatal infections, and reduces gestational age-dependent morbidity (16, 74, 75). The optimal antibiotic regimen is unclear because mul- tiple regimens have demonstrated benefit. Based on avail- able information, in order to reduce maternal and neonatal infections and gestational-age dependent morbidity, a 7-day course of therapy with a combination of intravenous ampicillin and erythromycin followed by oral amoxicil- lin and erythromycin is recommended during expectant management of women with preterm PROM who are less than 34 0/7 weeks of gestation (16, 74). The regimen used in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network trial was intravenous ampicillin (2 g every 6 hours) and erythromycin (250 mg every 6 hours) for 48 hours followed by oral amoxicillin (250 mg every 8 hours) and erythromycin base (333 mg every 8 hours) (75). The use of amoxicillin–clavulanic acid has been associated with increased rates of necrotiz- ing enterocolitis and it is not recommended (16, 74). Although there are no well-studied alternative regimens for women allergic to β-lactam antibiotics, it may be rea- sonable to administer erythromycin alone. Women with preterm PROM and a viable fetus who are candidates for intrapartum GBS prophylaxis should receive intrapartum GBS prophylaxis to prevent vertical transmission regard- less of earlier treatments (41, 76, 77). Should preterm PROM be managed with home care? The outpatient management of preterm PROM with a viable fetus has not been sufficiently studied to establish safety and, therefore, is not recommended. Two small ran- domized controlled trials that compared hospitalization to
  • 62. home care of women with preterm PROM had insufficient power to demonstrate a meaningful difference in outcome because only 11–18% of the women were eligible for ante- partum home care (78, 79). Because latency is frequently brief, infection may present suddenly and the fetus is at increased risk of umbilical cord compression, hospital- ization with surveillance of the woman and her fetus is recommended once viability has been reached. How should a patient with preterm PROM and a cervical cerclage be treated? There are no prospective studies with which to guide the care of women with preterm PROM who have a cervi- cal cerclage. Results from retrospective studies have not been consistent, but generally have found that cerclage retention for more than 24 hours after preterm PROM is associated with pregnancy prolongation (80); however, because of the nonrandomized nature of the reports, it is unclear how factors, such as labor or infection, con- tributed to decisions for cerclage removal, which may have yielded biased results. In some, but not all studies, cerclage retention with preterm PROM has been associ- ated with increased rates of neonatal mortality from sep- sis, neonatal sepsis, respiratory distress syndrome, and maternal chorioamnionitis (80, 81). A firm recommendation whether a cerclage should be removed after premature PROM cannot be made, and either removal or retention is reasonable. Regardless, if a cerclage remains in place with preterm PROM, prolonged antibiotic prophylaxis beyond 7 days is not recommended. What is the optimal management of a patient
  • 63. with preterm PROM and herpes simplex virus infection or human immunodeficiency virus? Neonatal herpes simplex virus (HSV) infection usually results from maternal–fetal transmission during delivery. The risk of vertical transmission with delivery in primary HSV is reported to be between 30% and 50%, compared with only 3% in cases of recurrent HSV (82). The litera- ture regarding expectant management of preterm PROM with active maternal HSV infection is limited to small case series and case reports (83, 84). All patients were treated with acyclovir, and cesarean delivery was per- formed if lesions were present at the time of delivery. No cases of vertical transmission were reported. The risk of prematurity should be weighed against the potential risk of neonatal HSV infection. In the set- ting of PROM with recurrent active infection, expectant management is recommended before 34 0/7 weeks of gestation. Herpes simplex virus therapy should be initi- ated, and corticosteroids, antibiotics, and magnesium sulfate for neuroprotection should be provided as clini- cally indicated. If active disease or prodromal symptoms are present at the onset of labor or when delivery is indi- cated, cesarean delivery is recommended. Optimal management of preterm PROM in the setting of primary HSV infection is less clear because of the increased risk of vertical transmission. Herpes simplex virus therapy is recommended, and if lesions are present at the time of delivery, cesarean delivery is recommended. The optimal management of the patient with HIV and preterm PROM is also uncertain because there are no adequate data from patients with prolonged rupture
  • 64. of the membranes. Early observations showed that the 924 Practice Bulletin Premature Rupture of Membranes OBSTETRICS & GYNECOLOGY duration of membrane rupture in labor correlated with risk of transmission to the newborn (85), but current data suggest that the duration of membrane rupture is not cor- related with risk of vertical transmission in patients who receive highly-active antiretroviral therapy, have a low viral load, and receive antepartum and intrapartum zid- ovudine (86). Also, a series of 10 patients with preterm PROM who were managed expectantly while receiving antiretroviral therapy, had no cases of HIV transmission to the newborn despite viral loads as high as 23,000 cop- ies per mL; the latent periods ranged from 4 hours to 4 days in this series, and all patients were delivered by cesarean (87). The management of patients with HIV infection who have preterm PROM should be individualized, with con- sideration of factors, including gestational age, current antiretroviral regimen, and viral load. In cases where the gestational age is very early, the patient is being treated with antiretroviral medications, and the viral load is low, a period of expectant management may be appropriate. In all cases, the patient should be managed in consulta- tion with a physician with expertise in management of HIV in pregnancy. Furthermore, standard antepartum and intrapartum treatment guidelines should be followed and management choices should be fully discussed with the patient (88). How does care differ for patients with PROM
  • 65. that occurs before neonatal viability? Women presenting with PROM before neonatal viability should be counseled regarding the risks and benefits of expectant management versus immediate delivery. Counseling should include a realistic appraisal of neo- natal outcomes. Immediate delivery should be offered. Attempts should be made to provide parents with the most current and accurate information possible (89). If the patient opts for expectant management and is clinically stable with no evidence of infection, outpatient surveillance can be considered. Precautions should be reviewed with the patient and she should come to the hospital if she develops symptoms of infection, labor, or abruptio placentae. It may be useful to instruct patients to monitor temperatures. Typically, women with previ- able PROM who have been cared for as outpatients are admitted to the hospital once the pregnancy has reached viability. Administration of antenatal corticosteroids and latency antibiotics for fetal maturation upon reach- ing viability is appropriate given that early delivery remains likely. Multiple ultrasonographic methods (such as thoracic measurements and ratios, flow velocities in pulmonary vessels, and three-dimensional estimations of lung volume) have been studied to evaluate pulmonary development in the antepartum period, but all are of lim- ited accuracy and cannot be considered sufficiently reli- able for clinical management (30). There is insufficient evidence to support the use of latency antibiotics with PROM before viability. Similarly, there is no evidence to support the use of tocolytics in the setting of previable preterm PROM, and in this setting, tocolytics should not
  • 66. be used. What is the expected outcome of PROM after second-trimester amniocentesis? In studies of women undergoing second-trimester amni- ocentesis for prenatal diagnosis of genetic disorders, the risk of PROM is approximately 1% (90, 91). In contrast to patients with spontaneous PROM in the second trimester, reaccumulation of normal amniotic fluid vol- ume and favorable outcomes are expected. In one series of 11 patients with PROM after genetic amniocentesis, there was one previable pregnancy loss, reaccumula- tion of normal amniotic fluid occurred within 1 month in 72% of patients, and the perinatal survival rate was 91% (90). After appropriate counseling, patients with PROM after genetic amniocentesis typically are managed expec- tantly as outpatients. Precautions regarding symptoms of chorioamnionitis and miscarriage should be given. Regular follow-up visits with ultrasonographic examina- tions to assess amniotic fluid volume are recommended. How should a patient with a history of preterm PROM be managed in future pregnancies? Patients with prior preterm PROM have an increased risk of recurrent PROM and preterm birth, and a detailed medical history should be taken. However, there are few studies that examine interventions to prevent recurrent PROM. Patients with a history of preterm PROM were included in studies of progesterone supplementation for preterm birth recurrence reduction, but most studies did not report the specific proportion of women with PROM
  • 67. in the study group or separately analyze results in those patients (92, 93). However, given the potential benefit of progesterone therapy, women with a single gestation and a prior spontaneous preterm birth (due to either labor with intact membranes or PROM) should be offered progesterone supplementation starting at 16 weeks to 24 weeks of gestation to reduce the risk of recurrent sponta- neous preterm birth. Although vaginal ultrasonographic measurement of the cervix is a safe and reliable means of evaluating the risk of preterm birth related to cervical length, there have been VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin Premature Rupture of Membranes 925 no well-designed trials of cervical surveillance in women with a history of PROM. Similar to the progesterone studies, women with prior PROM were included in trials that evaluated cervical assessment, vaginal progesterone, and cerclage but their specific data were not reported (94, 95). Thus, as with women with spontaneous preterm births, consideration can be given to transvaginal cervi- cal length screening. Cerclage placement is associated with significant decreases in preterm birth outcomes, offers perinatal benefits, and may be considered in women with the following combination of history and ultrasound findings: a current singleton pregnancy, prior spontaneous preterm birth at less than 34 weeks of gestation, and short cervical length (less than 25 mm) before 24 weeks of gestation (96). There are no data on which to base a recommendation regarding the optimal gestational age for initiating surveillance or frequency of monitoring.
  • 68. Summary of Recommendations and Conclusions The following recommendations are based on good and consistent scientific evidence (Level A): Patients with PROM before 34 0/7 weeks of gesta- tion should be managed expectantly if no maternal or fetal contraindications exist. To reduce maternal and neonatal infections and gestational-age dependent morbidity, a 7-day course of therapy with a combination of erythromycin and ampicillin or amoxicillin is recommended during expectant management of women with preterm PROM who are less than 34 0/7 weeks of gestation. Women with preterm PROM and a viable fetus who are candidates for intrapartum GBS prophy- laxis should receive intrapartum GBS prophylaxis to prevent vertical transmission regardless of earlier treatments. A single course of corticosteroids is recommended for pregnant women between 24 0/7 weeks and 34 0/7 weeks of gestation who are at risk of preterm delivery. Women with preterm PROM before 32 0/7 weeks of gestation who are thought to be at risk of imminent delivery should be considered candidates for fetal neuroprotective treatment with intravenous magne- sium sulfate. The following recommendations and conclusions
  • 69. are based on limited and inconsistent scientific evidence (Level B): For women with PROM at 37 0/7 weeks of gesta- tion or more, if spontaneous labor does not occur near the time of presentation in those who do not have contraindications to labor, labor should be induced. At 34 0/7 weeks or greater gestation, delivery is recommended for all women with ruptured membranes. In the setting of ruptured membranes with active labor, therapeutic tocolysis has not been shown to prolong latency or improve neonatal outcomes. Therefore, therapeutic tocolysis is not recommended. The following conclusion is based primarily on consensus and expert opinion (Level C): The outpatient management of preterm PROM with a viable fetus has not been sufficiently studied to establish safety and, therefore, is not recommended. Proposed Performance Measure The percentage of expectantly managed patients with preterm PROM (up to 34 0/7 weeks of gestation) that receive latency antibiotics and corticosteroids References 1. Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Wilson EC, Mathews TJ. Births: final data for 2010. Natl Vital Stat Rep 2012;61(1):1–71. (Level II-3)
  • 70. 2. Mathews TJ, MacDorman MF. Infant mortality statistics from the 2006 period linked birth/infant death data set. Natl Vital Stat Rep 2010;58:1–31. (Level II-3) [PubMed] 3. Waters TP, Mercer B. Preterm PROM: prediction, pre- vention, principles. Clin Obstet Gynecol 2011;54:307–12. (Level III) [PubMed] 4. Moore RM, Mansour JM, Redline RW, Mercer BM, Moore JJ. The physiology of fetal membrane rupture: insight gained from the determination of physical proper- ties. Placenta 2006;27:1037–51. (Level III) [PubMed] 5. Mercer BM. Preterm premature rupture of the mem- branes. Obstet Gynecol 2003;101:178–93. (Level III) [PubMed] [Obstetrics & Gynecology] 6. Garite TJ, Freeman RK. Chorioamnionitis in the preterm gestation. Obstet Gynecol 1982;59:539–45. (Level II-3) [PubMed] [Obstetrics & Gynecology] http://www.ncbi.nlm.nih.gov/pubmed/20815136 http://www.ncbi.nlm.nih.gov/pubmed/21508700 http://www.ncbi.nlm.nih.gov/pubmed/16516962 http://www.ncbi.nlm.nih.gov/pubmed/12517665 http://journals.lww.com/greenjournal/Fulltext/2003/01000/Prete rm_Premature_Rupture_of_the_Membranes.33.aspx http://www.ncbi.nlm.nih.gov/pubmed/7070724 http://journals.lww.com/greenjournal/Abstract/1982/05000/Chor ioamnionitis_in_the_Preterm_Gestation.1.aspx 926 Practice Bulletin Premature Rupture of Membranes OBSTETRICS & GYNECOLOGY
  • 71. 7. Mercer BM, Goldenberg RL, Moawad AH, Meis PJ, Iams JD, Das AF, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999;181:1216–21. (Level II-2) [PubMed] 8. Asrat T, Lewis DF, Garite TJ, Major CA, Nageotte MP, Towers CV, et al. Rate of recurrence of preterm prema- ture rupture of membranes in consecutive pregnancies. Am J Obstet Gynecol 1991;165:1111–5. (Level II-2) [PubMed] 9. Mercer BM, Goldenberg RL, Meis PJ, Moawad AH, Shellhaas C, Das A, et al. The Preterm Prediction Study: prediction of preterm premature rupture of mem- branes through clinical findings and ancillary testing. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 2000;183:738–45. (Level II-2) [PubMed] [Full Text] 10. Harger JH, Hsing AW, Tuomala RE, Gibbs RS, Mead PB, Eschenbach DA, et al. Risk factors for preterm premature rupture of fetal membranes: a multicenter case-control study. Am J Obstet Gynecol 1990;163:130–7. (Level II-2) [PubMed] 11. Berkowitz GS, Blackmore-Prince C, Lapinski RH, Savitz DA. Risk factors for preterm birth subtypes. Epidemiology 1998;9:279–85. (Level II-3) [PubMed] 12. Treadwell MC, Bronsteen RA, Bottoms SF. Prognostic factors and complication rates for cervical cerclage: a review of 482 cases. Am J Obstet Gynecol 1991;165:
  • 72. 555–8. (Level II-3) [PubMed] 13. Hannah ME, Ohlsson A, Farine D, Hewson SA, Hodnett ED, Myhr TL, et al. Induction of labor compared with expectant management for prelabor rupture of the mem- branes at term. TERMPROM Study Group. N Engl J Med 1996;334:1005–10. (Level I) [PubMed] [Full Text] 14. Melamed N, Hadar E, Ben-Haroush A, Kaplan B, Yogev Y. Factors affecting the duration of the latency period in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2009;22:1051– 6. (Level II-3) [PubMed] [Full Text] 15. Johnson JW, Egerman RS, Moorhead J. Cases with ruptured membranes that “reseal”. Am J Obstet Gynecol 1990;163:1024–30; discussion 1030–2. (Level II-2) [PubMed] 16. Kenyon S, Boulvain M, Neilson JP. Antibiotics for pre- term rupture of membranes. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001058. DOI: 10.1002/14651858.CD001058.pub2. (Meta-analysis) [PubMed] [Full Text] 17. Beydoun SN, Yasin SY. Premature rupture of the mem- branes before 28 weeks: conservative management. Am J Obstet Gynecol 1986;155:471–9. (Level III) [PubMed] 18. Major CA, de Veciana M, Lewis DF, Morgan MA. Preterm premature rupture of membranes and abruptio placentae: is there an association between these pregnancy complica- tions? Am J Obstet Gynecol 1995;172:672–6. (Level II-3) [PubMed] [Full Text] 19. Ananth CV, Oyelese Y, Srinivas N, Yeo L, Vintzileos
  • 73. AM. Preterm premature rupture of membranes, intra- uterine infection, and oligohydramnios: risk factors for placental abruption. Obstet Gynecol 2004;104:71–7. (Level II-3) [PubMed] [Obstetrics & Gynecology] 20. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institute of Child health and human develop- ment neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001;107:E1. (Level II-3) [PubMed] [Full Text] 21. Spinillo A, Capuzzo E, Stronati M, Ometto A, Orcesi S, Fazzi E. Effect of preterm premature rupture of mem- branes on neurodevelopmental outcome: follow up at two years of age. Br J Obstet Gynaecol 1995;102:882–7. (Level II-2) [PubMed] 22. Yoon BH, Romero R, Park JS, Kim CJ, Kim SH, Choi JH, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol 2000;182:675–81. (Level II-2) [PubMed] 23. Locatelli A, Ghidini A, Paterlini G, Patane L, Doria V, Zorloni C, et al. Gestational age at preterm premature rupture of membranes: a risk factor for neonatal white matter damage. Am J Obstet Gynecol 2005;193:947–51. (Level II-3) [PubMed] [Full Text] 24. Mercer BM, Arheart KL. Antimicrobial therapy in expectant management of preterm premature rupture of the membranes [published erratum appears in Lancet 1996;347:410]. Lancet 1995;346:1271–9. (Meta-analysis) [PubMed] [Full Text]
  • 74. 25. Manuck TA, Eller AG, Esplin MS, Stoddard GJ, Varner MW, Silver RM. Outcomes of expectantly managed pre- term premature rupture of membranes occurring before 24 weeks of gestation. Obstet Gynecol 2009;114:29–37. (Level II-3) [PubMed] [Obstetrics & Gynecology] 26. Waters TP, Mercer BM. The management of preterm pre- mature rupture of the membranes near the limit of fetal via- bility. Am J Obstet Gynecol 2009;201:230–40. (Level III) [PubMed] [Full Text] 27. Schucker JL, Mercer BM. Midtrimester premature rupture of the membranes. Semin Perinatol 1996;20:389–400. (Level III) [PubMed] 28. Muris C, Girard B, Creveuil C, Durin L, Herlicoviez M, Dreyfus M. Management of premature rupture of mem- branes before 25 weeks. Eur J Obstet Gynecol Reprod Biol 2007;131:163–8. (Level III) [PubMed] [Full Text] 29. Farooqi A, Holmgren PA, Engberg S, Serenius F. Survival and 2-year outcome with expectant management of second-trimester rupture of membranes. Obstet Gynecol 1998;92:895–901. (Level II-3) [PubMed] [Obstetrics & Gynecology] 30. van Teeffelen AS, van der Ham DP, Oei SG, Porath MM, Willekes C, Mol BW. The accuracy of clinical parameters in the prediction of perinatal pulmonary hypoplasia sec- ondary to midtrimester prelabour rupture of fetal mem- branes: a meta-analysis. Eur J Obstet Gynecol Reprod http://www.ncbi.nlm.nih.gov/pubmed/10561648 http://www.ncbi.nlm.nih.gov/pubmed/1951524 http://www.ncbi.nlm.nih.gov/pubmed/10992202
  • 75. http://www.sciencedirect.com/science/article/pii/S00029378006 45696/pdf?md5=3ce6096f67352b916265c86130581587&pid=1- s2.0-S0002937800645696-main.pdf http://www.ncbi.nlm.nih.gov/pubmed/2197863 http://www.ncbi.nlm.nih.gov/pubmed/9583419 http://www.ncbi.nlm.nih.gov/pubmed/1892180 http://www.ncbi.nlm.nih.gov/pubmed/8598837 http://www.nejm.org/doi/full/10.1056/NEJM199604183341601# t=article http://www.ncbi.nlm.nih.gov/pubmed/19900043 http://informahealthcare.com/doi/full/10.3109/14767050903019 650 http://www.ncbi.nlm.nih.gov/pubmed/2206055 http://www.ncbi.nlm.nih.gov/pubmed/20687063 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001058 .pub2/full http://www.ncbi.nlm.nih.gov/pubmed/3752169 http://www.ncbi.nlm.nih.gov/pubmed/7856704 http://www.sciencedirect.com/science/article/pii/000293789590 591X/pdf?md5=09506f1981dadfa14ebf88302236e832&pid=1- s2.0-000293789590591X-main.pdf http://www.ncbi.nlm.nih.gov/pubmed/15229003 http://journals.lww.com/greenjournal/Fulltext/2004/07000/Prete rm_Premature_Rupture_of_Membranes,.12.aspx http://www.ncbi.nlm.nih.gov/pubmed/11134465 http://pediatrics.aappublications.org/content/107/1/e1.long http://pediatrics.aappublications.org/content/107/1/e1.long http://www.ncbi.nlm.nih.gov/pubmed/8534623 http://www.ncbi.nlm.nih.gov/pubmed/10739529 http://www.ncbi.nlm.nih.gov/pubmed/16157092 http://www.sciencedirect.com/science/article/pii/S00029378050 08835 http://www.ncbi.nlm.nih.gov/pubmed/7475723 http://www.sciencedirect.com/science/article/pii/S01406736959 1868X/pdf?md5=351cc9331e911244571ff1f5f1bd7d87&pid=1- s2.0-S014067369591868X-main.pdf
  • 76. http://www.ncbi.nlm.nih.gov/pubmed/19546755 http://journals.lww.com/greenjournal/Fulltext/2009/07000/Outc omes_of_Expectantly_Managed_Preterm_Premature.7.aspx http://www.ncbi.nlm.nih.gov/pubmed/19733274 http://www.sciencedirect.com/science/article/pii/S00029378090 06930 http://www.ncbi.nlm.nih.gov/pubmed/8912993 http://www.ncbi.nlm.nih.gov/pubmed/16846673 http://www.sciencedirect.com/science/article/pii/S03012115060 02843 http://www.ncbi.nlm.nih.gov/pubmed/9840545 http://journals.lww.com/greenjournal/Abstract/1998/12000/Surv ival_and_2_Year_Outcome_With_Expectant.1.aspx http://journals.lww.com/greenjournal/Abstract/1998/12000/Surv ival_and_2_Year_Outcome_With_Expectant.1.aspx VOL. 122, NO. 4, OCTOBER 2013 Practice Bulletin Premature Rupture of Membranes 927 Biol 2010;148:3–12. (Meta-analysis) [PubMed] [Full Text] 31. van Teeffelen AS, Van Der Heijden J, Oei SG, Porath MM, Willekes C, Opmeer B, et al. Accuracy of imaging parameters in the prediction of lethal pulmonary hypo- plasia secondary to mid-trimester prelabor rupture of fetal membranes: a systematic review and meta-analy- sis. Ultrasound Obstet Gynecol 2012;39:495–9. (Meta- analysis) [PubMed] [Full Text] 32. Blott M, Greenough A. Neonatal outcome after prolonged rupture of the membranes starting in the second trimester. Arch Dis Child 1988;63:1146–50. (Level III) [PubMed] [Full Text]
  • 77. 33. Alexander JM, Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, et al. The impact of digital cervical examination on expectantly managed preterm rupture of membranes. Am J Obstet Gynecol 2000;183: 1003–7. (Level II-2) [PubMed] [Full Text] 34. Munson LA, Graham A, Koos BJ, Valenzuela GJ. Is there a need for digital examination in patients with spontane- ous rupture of the membranes? Am J Obstet Gynecol 1985;153:562–3. (Level III) [PubMed] 35. Eriksen NL, Parisi VM, Daoust S, Flamm B, Garite TJ, Cox SM. Fetal fibronectin: a method for detecting the presence of amniotic fluid. Obstet Gynecol 1992;80: 451–4. (Level II-2) [PubMed] [Obstetrics & Gynecology] 36. Lee SE, Park JS, Norwitz ER, Kim KW, Park HS, Jun JK. Measurement of placental alpha-microglobulin-1 in cer- vicovaginal discharge to diagnose rupture of membranes. Obstet Gynecol 2007;109:634–40. (Level II-3) [PubMed] [Obstetrics & Gynecology] 37. Cousins LM, Smok DP, Lovett SM, Poeltler DM. AmniSure placental alpha microglobulin-1 rapid immu- noassay versus standard diagnostic methods for detec- tion of rupture of membranes. Am J Perinatol 2005;22: 317–20. (Level II-3) [PubMed] [Full Text] 38. Lee SM, Lee J, Seong HS, Lee SE, Park JS, Romero R, et al. The clinical significance of a positive Amnisure test in women with term labor with intact membranes. J Matern Fetal Neonatal Med 2009;22:305–10. (Level II-3) [PubMed] [Full Text] 39. Lee SM, Romero R, Park JW, Kim SM, Park CW,
  • 78. Korzeniewski SJ, et al. The clinical significance of a positive Amnisure test in women with preterm labor and intact membranes. J Matern Fetal Neonatal Med 2012;25: 1690–8. (Level II-2) [PubMed] [Full Text] 40. Smith CV, Greenspoon J, Phelan JP, Platt LD. Clinical utility of the nonstress test in the conservative manage- ment of women with preterm spontaneous premature rupture of the membranes. J Reprod Med 1987;32:1–4. (Level II-3) [PubMed] 41. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease––revised guidelines from CDC, 2010. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2010;59(RR-10):1–36. (Level I) [PubMed] [Full Text] 42. Dare MR, Middleton P, Crowther CA, Flenady V, Varatharaju B. Planned early birth versus expectant man- agement (waiting) for prelabour rupture of membranes at term (37 weeks or more). Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005302. DOI: 10.1002/14651858.CD005302.pub2. (Meta-analysis) [PubMed] [Full Text] 43. Flenady V, King JF. Antibiotics for prelabour rupture of membranes at or near term. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD001807. DOI: 10.1002/14651858.CD001807. (Meta-analysis) [PubMed] [Full Text] 44. Ovalle A, Martinez MA, Kakarieka E, Gomez R, Rubio R, Valderrama O, et al. Antibiotic administration in patients with preterm premature rupture of membranes reduces
  • 79. the rate of histological chorioamnionitis: a prospective, randomized, controlled study. J Matern Fetal Neonatal Med 2002;12:35–41. (Level I) [PubMed] [Full Text] 45. Cararach V, Botet F, Sentis J, Almirall R, Perez-Picanol E. Administration of antibiotics to patients with rupture of membranes at term: a prospective, randomized, multicen- tric study. Collaborative Group on PROM. Acta Obstet Gynecol Scand 1998;77:298–302. (Level I) [PubMed] [Full Text] 46. Rouse DJ, Weiner SJ, Bloom SL, Varner MW, Spong CY, Ramin SM, et al. Failed labor induction: toward an objec- tive diagnosis. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). Obstet Gynecol 2011;117:267–72. (Level III) [PubMed] [Obstetrics & Gynecology] 47. Rouse DJ, Owen J, Hauth JC. Criteria for failed labor induction: prospective evaluation of a standardized protocol. Obstet Gynecol 2000;96:671–7. (Level II-3) [PubMed] [Obstetrics & Gynecology] 48. Simon CE, Grobman WA. When Has an Induction Failed? Obstet Gynecol 2005;105:705–9. (Level II-2) [PubMed] [Obstetrics & Gynecology] 49. Buchanan SL, Crowther CA, Levett KM, Middleton P, Morris J. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks’ gestation for improving pregnancy outcome. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD004735. DOI: 10.1002/ 14651858.CD004735.pub3. (Meta-analysis) [PubMed] [Full Text]
  • 80. 50. van der Ham DP, van der Heyden JL, Opmeer BC, Mulder AL, Moonen RM, van Beek JH, et al. Management of late-preterm premature rupture of membranes: the PPROMEXIL-2 trial. Am J Obstet Gynecol 2012;207:276. e1–276.10. (Level I) [PubMed] [Full Text] 51. van der Ham DP, Vijgen SM, Nijhuis JG, van Beek JJ, Opmeer BC, Mulder AL, et al. Induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks: a ran- domized controlled trial. PPROMEXIL trial group. PLoS Med 2012;9:e1001208. (Level I) [PubMed] [Full Text] 52. Naef RW 3rd, Allbert JR, Ross EL, Weber BM, Martin RW, Morrison JC. Premature rupture of membranes at http://www.ncbi.nlm.nih.gov/pubmed/19892458 http://www.sciencedirect.com/science/article/pii/S03012115090 05934 http://www.sciencedirect.com/science/article/pii/S03012115090 05934 http://www.ncbi.nlm.nih.gov/pubmed/21793083 http://onlinelibrary.wiley.com/doi/10.1002/uog.10047/full http://www.ncbi.nlm.nih.gov/pubmed/3196069 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1590218/pdf/arc hdisch00903-0034.pdf http://www.ncbi.nlm.nih.gov/pubmed/11035354 http://www.sciencedirect.com/science/article/pii/S00029378008 63036/pdf?md5=8bee388b8dc5369c41a3f7d6ede65b13&pid=1- s2.0-S0002937800863036-main.pdf http://www.ncbi.nlm.nih.gov/pubmed/4061518 http://www.ncbi.nlm.nih.gov/pubmed/1495705 http://journals.lww.com/greenjournal/Abstract/1992/09000/Fetal _Fibronectin__A_Method_for_Detecting_the.28.aspx http://www.ncbi.nlm.nih.gov/pubmed/17329514
  • 81. http://journals.lww.com/greenjournal/Fulltext/2007/03000/Meas urement_of_Placental_Alpha_Microglobulin_1_in.9.aspx http://www.ncbi.nlm.nih.gov/pubmed/16118720 https://www.thieme-connect.com/ejournals/html/10.1055/s- 2005-870896 http://www.ncbi.nlm.nih.gov/pubmed/19350444 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744034/ http://www.ncbi.nlm.nih.gov/pubmed/22280400 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422421/ http://www.ncbi.nlm.nih.gov/pubmed/3560057 http://www.ncbi.nlm.nih.gov/pubmed/21088663 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5910a1.htm http://www.ncbi.nlm.nih.gov/pubmed/16437525 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005302 .pub2/full http://www.ncbi.nlm.nih.gov/pubmed/12137635 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001807 /full http://www.ncbi.nlm.nih.gov/pubmed/12422907 http://informahealthcare.com/doi/pdf/10.1080/jmf.12.1.35.41 http://www.ncbi.nlm.nih.gov/pubmed/9580172 http://onlinelibrary.wiley.com/doi/10.1034/j.1600- 0412.1998.770308.x/pdf http://www.ncbi.nlm.nih.gov/pubmed/21252738 http://journals.lww.com/greenjournal/Fulltext/2011/02000/Faile d_Labor_Induction__Toward_an_Objective.10.aspx http://www.ncbi.nlm.nih.gov/pubmed/11042299 http://journals.lww.com/greenjournal/Fulltext/2000/11000/Crite ria_for_Failed_Labor_Induction__Prospective.6.aspx http://www.ncbi.nlm.nih.gov/pubmed/15802394 http://journals.lww.com/greenjournal/Fulltext/2005/04000/When _Has_an_Induction_Failed_.5.aspx http://www.ncbi.nlm.nih.gov/pubmed/20238332 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004735 .pub3/full http://www.ncbi.nlm.nih.gov/pubmed/22901981
  • 82. http://www.sciencedirect.com/science/article/pii/S00029378120 07764 http://www.ncbi.nlm.nih.gov/pubmed/22545024 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335867/ 928 Practice Bulletin Premature Rupture of Membranes OBSTETRICS & GYNECOLOGY 34 to 37 weeks’ gestation: aggressive versus conservative management. Am J Obstet Gynecol 1998;178:126–30. (Level I) [PubMed] 53. Mercer BM, Crocker LG, Boe NM, Sibai BM. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial. Am J Obstet Gynecol 1993;169: 775–82. (Level I) [PubMed] 54. Teune MJ, Bakhuizen S, Gyamfi Bannerman C, Opmeer BC, van Kaam AH, van Wassenaer AG, et al. A sys- tematic review of severe morbidity in infants born late preterm. Am J Obstet Gynecol 2011;205:374.e1–374.e9. (Meta-analysis) [PubMed] [Full Text] 55. McGowan JE, Alderdice FA, Holmes VA, Johnston L. Early childhood development of late-preterm infants: a systematic review. Pediatrics 2011;127:1111–24. (Level III) [PubMed] [Full Text] 56. Melamed N, Ben-Haroush A, Pardo J, Chen R, Hadar E, Hod M, et al. Expectant management of preterm prema- ture rupture of membranes: is it all about gestational age? Am J Obstet Gynecol 2011;204:48.e1–48.e8. (Level II-3) [PubMed] [Full Text]